Amendment No. 3 to Form F-1

As filed with the Securities and Exchange Commission on July 18, 2014

Registration no. 333-196584

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Amendment No. 3

to

Form F-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

VASCULAR BIOGENICS LTD.

(Exact Name of Registrant as Specified in Its Charter)

 

 

N/A

(Translation of Registrant’s Name into English)

 

 

 

Israel   2834   Not applicable

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

Vascular Biogenics Ltd.

6 Jonathan Netanyahu St.

Or Yehuda

Israel 60376

972-3-634-6450

(Address, Including ZIP Code, and Telephone Number,

Including Area Code, of Registrant’s Principal Executive Offices)

 

 

CT Corporation System

111 8th Avenue

New York, New York 10011

(212) 894-8800

(Name, Address, Including ZIP Code, and Telephone Number,

Including Area Code, of Agent for Service)

 

 

Copies to:

 

Mitchell S. Bloom, Esq.

Lawrence S. Wittenberg, Esq.

Goodwin Procter LLP

Exchange Place

53 State Street

Boston, MA 02109

(617) 570-1000

 

Yuval Horn, Adv.

Keren Kanir, Adv.

Horn & Co, Law Offices

Amot Investments Tower

2 Weizmann St., 24th Floor

Tel Aviv, Israel 6423902

972-3-637-8200

 

Brent B. Siler

Darren K. DeStefano

Cooley LLP

11951 Freedom Drive

Reston, VA 20190

(703) 456-8000

 

Chaim Friedland, Adv.

Ari Fried, Adv.

Gornitzky & Co.

Zion House, 45 Rothschild Blvd.

Tel Aviv, Israel 6578403

972-3-710-9191

Approximate date of commencement of proposed offering to the public: As soon as practicable after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ¨

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 


Explanatory Note

The sole purpose of this Amendment No. 3 to the Registration Statement on Form F-1 is to amend the exhibit index and to submit exhibits 10.3, 10.4, 10.5, 10.7, 10.8, 10.9, 10.10, 10.11, 10.12, 10.13 and 10.15. Accordingly, this Amendment No. 3 consists only of this explanatory note and Part II, including the signature page and the exhibit index. This Amendment No. 3 does not contain a copy of the prospectus that was included in Amendment No. 2 to the Draft Registration Statement on Form F-1 and is not intended to amend or delete any part of the prospectus.


PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 6. Indemnification of Officer Holders (Including Directors).

Under the Israeli Companies Law 1999, or the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in the company’s articles of association. Our articles of association to be effective immediately prior to the closing of this offering include such a provision. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.

Under the Companies Law, a company may indemnify an office holder for the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking given by the company in advance of the act or following the act, provided its articles of association authorize such indemnification:

 

   

a monetary liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount, or according to criteria, determined by the board of directors as reasonable under the circumstances. Such undertaking shall detail the foreseen events and amount or criteria mentioned above;

 

   

reasonable litigation expenses, including reasonable attorneys’ fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent (mens rea); and (2) in connection with a monetary sanction; and

 

   

reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent (mens rea).

In addition, under the Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder, if and to the extent provided in the company’s articles of association:

 

   

a breach of a duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;

 

   

a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and

 

   

a monetary liability imposed on the office holder in favor of a third party.

 

II-1


Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:

 

   

a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;

 

   

a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;

 

   

an act or omission committed with intent to derive illegal personal benefit; or

 

   

a fine or penalty levied against the office holder.

Under the Companies Law, for the approval of exculpation, indemnification and insurance of office holders who are executive officers, directors and controlling shareholders, see the section of the prospectus that forms a part of this Registration Statement entitled “Management—Approval of Related Party Transactions Under Israeli Law.”

Our amended and restated articles of association to be effective immediately prior the closing of this offering permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted under the Companies Law (other than indemnification for litigation expenses in connection with a monetary sanction).

We have entered into indemnification and exculpation agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by the Companies Law and undertaking to indemnify them to the fullest extent permitted by the Companies Law.

We are not aware of any pending or threatened litigation or proceeding involving any of our office holders as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any office holder.

The proposed form of Underwriting Agreement filed as Exhibit 1.1 to this Registration Statement provides for indemnification of our office holders by the underwriters against certain liabilities.

Item 7. Recent Sales of Unregistered Securities.

Since January 1, 2011, after giving effect to the 1-to-4.5 forward share split of our shares to be effected prior to the completion of this offering:

 

   

We have granted options to purchase an aggregate of 531,166 ordinary shares to our directors, officers, employees and service providers, in each case having an exercise price of $3.32 per share.

 

   

We have issued and sold 154,634 ordinary shares pursuant to the exercise of options held by our directors, officers and employees, having a weighted average exercise price per share of $1.72.

 

   

In January 2011, we issued 343,080 Series D preferred shares at $11.21 per share to 11 investors.

 

   

On April 30, 2013, we issued a convertible loan in the aggregate principal amount of approximately $10.0 million to 10 investors.

 

   

In May 2014, we issued an aggregate of 1,495,331 Series E preferred shares to 21 investors, consisting of 413,096 Series E preferred shares at a purchase price of $11.95 per share and 1,082,235 Series E preferred shares issued upon conversion of our convertible loan that we received on July 1, 2013.

 

II-2


The sales and issuances of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon (i) Section 4(2) of the Securities Act, including Regulation S promulgated thereunder, as transactions by an issuer not involving any public offering or involving offers and sales of securities outside the United States (ii) Section 3(a)(9) of the Securities Act, as exchanges of our securities with our existing security holders and no commission or remuneration was paid or given directly or indirectly for soliciting such exchanges, or (iii) Rule 701, as issuances under our equity incentive plans.

Item 8. Exhibits and Financial Statement Schedules.

 

   

The Exhibit Index is hereby incorporated herein by reference.

 

   

Financial Statement Schedules.

All schedules have been omitted because they are not required, are not applicable or the information is otherwise set forth in the Financial Statements and related notes thereto.

Item 9. Undertakings.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes:

 

   

To provide the underwriters specified in the Underwriting Agreement, at the closing, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

 

   

That for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

   

That for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-3


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Amendment No. 3 to its Registration Statement on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on July 18, 2014.

 

VASCULAR BIOGENICS LTD.
By:   /s/    Dror Harats

Name: Dror Harats

Title: Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signatures

  

Title

 

Date

/s/    Dror Harats        

Dror Harats

  

Chief Executive Officer and Director

(Principal Executive Officer)

  July 18, 2014

*

Bennett M. Shapiro

  

Non-Executive Director

  July 18, 2014

*

Ruth Arnon

  

Non-Executive Director

  July 18, 2014

*

Jide J. Zeitlin

  

Non-Executive Director

  July 18, 2014

*

Jecheskiel Gonczarowski

  

Non-Executive Director

  July 18, 2014

*

Dan J. Gelvan

  

Non-Executive Director

  July 18, 2014

 

II-4


*

Ruth Alon

  

Non-Executive Director

  July 18, 2014

/s/    Amos Ron        

Amos Ron

  

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

  July 18, 2014

 

  Authorized Representative in the United States

/s/    Donald J. Puglisi

  July 18, 2014

Name: Donald J. Puglisi

 

Title: Authorized Representative in the United States

 

 

*By:  

/s/ Amos Ron

 

Amos Ron

 

Attorney-in-fact

 

II-5


EXHIBIT INDEX

 

Exhibit

No.

 

Description

  1.1*   Form of Underwriting Agreement.
  3.1**   Articles of Association of the Registrant as amended and in effect prior to this offering.
  3.2**   Amended and Restated Articles of Association of the Registrant to be effective immediately prior to the closing of this offering.
  3.3**   Memorandum of Association of the Registrant as amended and in effect prior to this offering.
  3.4**   Amendment to Memorandum of Association of the Registrant to be effective immediately prior to the closing of this offering.
  4.1**   Amended and Restated Investors’ Rights Agreement, dated as of March 13, 2008, by and among the Registrant and the other parties thereto, as amended.
  4.2*   Specimen share certificate.
  4.3**   Warrant to purchase ordinary shares, dated May 8, 2014, issued to S.R. Horn Assets Ltd.
  4.4**   Warrant to purchase ordinary shares, dated April 1, 2001, issued to Dror Harats, as amended.
  4.5**   Warrant to purchase ordinary shares, dated May 14, 2001, issued to Dror Harats, as amended.
  4.6**   Warrant to purchase ordinary shares, dated December 28, 2001, issued to Dror Harats, as amended.
  5.1*   Opinion of Horn & Co, Law Offices, Israeli legal counsel of the Registrant.
10.1!**  

Employee Ownership and Share Option Plan (2011) of the Registrant, and form of agreement thereunder.

10.2!**  

Form of Release and Indemnification Agreement to be entered into between the Registrant and its officers and directors.

10.3+   Commercial Gene Therapy License Agreement, dated April 15, 2011, between the Registrant and Crucell Holland B.V.
10.4+   Agreement, dated February 3, 2013, between the Registrant and Tel Hashomer—Medical Research, Infrastructure and Services Ltd.
10.5+   Manufacturing Services Agreement, dated January 5, 2012, between the Registrant and Lonza Houston, Inc.
10.6**   Master Services Agreement, dated May 14, 2008, between the Registrant and Genzyme Pharmaceuticals.
10.7+   Technical Agreement on the Manufacture of Capsules, dated April 29, 2008, between the Registrant and Encap Drug Delivery and standard terms and conditions of purchase order.
10.8+   Technical Agreement on the Manufacture of Capsules, dated August 3, 2012, between the Registrant and Encap Drug Delivery and standard terms and conditions of purchase order.
10.9+   Material Transfer and Confidentiality Agreement, effective as of September 19, 2005, among the Registrant, Crucell Holland B.V. and BioReliance Ltd.


Exhibit

No.

 

Description

10.10+   General Services Agreement, dated September 24, 2012, between the Registrant and BioClinica, Inc., and Addendum dated November 19, 2012 and August 29, 2013.
10.11+   Clinical Trial Agreement, dated September 9, 2012, between the Registrant and SCIderm GmbH.
10.12+   Service Agreement, dated November 8, 2012, between the Registrant and KCR S.A.
10.13+   Service Agreement, dated December 16, 2013, between the Registrant and KCR S.A.
10.14#**   Lease Agreement, dated January 2013, between the Registrant and Matzlawi Building Company Ltd.
10.15+   Material Transfer and Confidentiality Agreement, effective February 6, 2012 between the Registrant, Crucell Holland B.V. and Lonza Houston, Inc.
10.16**   Agreement between the Registrant and Prof. Jacob George, dated January 24, 2010, as amended on August 1, 2012.
10.17!**   Employee Share Ownership and Option Plan (2014) of the Registrant, and form of Capital Gains Option Agreement thereunder.
21.1**   Subsidiaries of the Registrant.
23.1**   Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, Independent Registered Public Accounting Firm.
23.2*   Consent of Horn & Co, Law Offices (included in Exhibit 5.1).
24.1**   Powers of Attorney (included on signature page to the original filing of this Registration Statement on Form F-1).

 

* To be filed by amendment.

 

** Previously filed.

 

! Management contract or plan.

 

+ Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request.

 

# English summary of original Hebrew document.
EX-10.3

Exhibit 10.3

CRUCELL HOLLAND B.V. – VASCULAR BIOGENICS LTD.

COMMERCIAL GENE THERAPY LICENSE AGREEMENT

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

COMMERCIAL GENE THERAPY LICENSE AGREEMENT

This Commercial Gene Therapy License Agreement (“Agreement”) is made and entered into on April 15, 2011 (“EFFECTIVE DATE”) by and between:

CRUCELL HOLLAND B.V., a corporation organized under the laws of the Netherlands, having offices located at Archimedesweg 4, 2333 CN, Leiden, the Netherlands “CRUCELL”)

and

VASCULAR BIOGENICS Ltd., with offices located at 6 Jonathan Netanyahu Street, 60376, Or-Yehuda, Israel (hereinafter referred to as “VBL” or “LICENSEE”),

the parties hereinafter individually referred to as “Party” and collectively as “Parties”.

PREAMBLE

 

    WHEREAS, CRUCELL is the owner of a PER.C6® cell line and of the associated information, know-how, and patents rights (as defined below);

 

    WHEREAS, LICENSEE is engaged in the business of biomedical research, and the manufacturing, testing and commercializing of pharmaceutical products and services;

 

    WHEREAS, LICENSEE and CRUCELL are parties to a Research License and Option Agreement dated March 24, 2005, granting LICENSEE the rights to conduct research under the PER.C6® PATENTS and to utilize PER.C6® KNOW HOW (as such terms are defined below) to prepare and evaluate gene therapeutics based on adenoviral vectors, and an option for a commercial license;

 

    WHEREAS, LICENSEE has exercised its option to a commercial license and the Parties have negotiated an agreement for commercial rights under the terms and conditions as set forth hereinafter;

NOW, THEREFORE, in consideration of the mutual covenants and promises set forth herein, the Parties, intending to be legally bound, agree as follows:

 

1. DEFINITIONS

Plural used in this Agreement shall mean singular and vice versa.

 

  1.1. AFFILIATE means any person, corporation, organization or other legal entity which, directly or indirectly, controls, or is controlled by, or is under common control with, a Party. CONTROL shall mean the ability, directly or indirectly, to direct the activities of the relevant entity, including the ownership or holding (directly or indirectly) of fifty percent (50%) or more of (i) the securities or other ownership interests representing the equity, the voting stock or general partnership interest, or (ii) the rights to elect or appoint directors (or other governing body).

 

  1.2. APPROVED COUNTRIES means the countries mentioned in Exhibit 1.2

 

  1.3. BMF means the PER.C6® Biologics Master File as filed with the United States Food and Drug Administration

 

  1.4. EFFECTIVE DATE has the meaning set forth in the first paragraph of this Agreement.

 

  1.5. FIELD means the treatment of cancer in human by administering to a subject an adenoviral vector including, but not limited to, therapeutic gene sequence(s), the therapeutic effect of which is principally caused by the expression product of said gene sequence(s) and will not serve as a vaccine.

 

1

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  1.6. FIRST COMMERCIAL SALE means the first sale of a PRODUCT in a country by LICENSEE or any of its SUBLICENSEES OR REGISTERED AFFILIATES.

 

  1.7. FUNCTIONAL GENOMICS means the identification and/or validation of the biological function(s) of human and animal genes, and/or gene fragments and/or proteins and/or fragments of proteins transcribed from such genes, by means of the construction and use of arrayed collections of said genes and/or gene fragments, in non-phage viral vectors, to enable the identification and validation of drug targets, nutriceuticals and/or protein therapeutics, for the treatment or prevention of human or animal disease(s) and/or the maintenance of nutritional health.

 

  1.8. GOVERMENTAL AUTHORITIES means the FDA and other foreign governmental equivalents.

 

  1.9. IMPROVEMENT KNOW HOW RIGHTS means know how rights owned or licensable by LICENSEE or its REGISTERED AFFILIATES, which are developed during the Term using the technology claimed by the IMPROVEMENT PATENT RIGHTS, and which (i) come into the possession of LICENSEE or its REGISTERED AFFILIATES during the course of PROGRAMS and during the TERM of this Agreement, (ii) are not generally known, (iii) are related to the subject matter(s) of the IMPROVEMENT PATENT RIGHTS and are necessary for CRUCELL’s practice of the IMPROVEMENT PATENT RIGHTS as permitted under Section 2.5, and (iv) are not subject to a good faith reasonable third party confidentiality obligation that prevents the disclosure of the same.

 

  1.10. IMPROVEMENT PATENT RIGHTS means any patent issued after the EFFECTIVE DATE only to the extent that it claims (i) a new use of the PACKAGING CELLS including a generic product by process using said cells, (ii) an improved cell line derived from the PACKAGING CELLS, (iii) culturing or processing of PACKAGING CELLS, or (iv) a new use of an improved cell line described in clause (ii) of this sentence, in each case that is developed during the course of PROGRAMS under this Agreement.

 

  1.11. MODIFIED CELLS means PER.C6® CELLS modified by incorporating therein VBL TECHNOLOGY, but excluding the integration thereof into the genome of the PER.C6® CELL.

 

  1.12. NET Sales means the gross amount invoiced on sales of the PRODUCTS by LICENSEE, SUBLICENSEES, REGISTERED AFFILIATES and/or their respective sub-licensees to customers, less the following deductions related to the sale and delivery of PRODUCTS: (i) any commercially reasonable credits and allowances, repayments or adjustments granted or made to customers; (ii) any commercially reasonable trade or cash discounts, rebates, charge-backs or administrative fees or other price reductions granted to customers; and (iii) any sales, transportation, import, export or other like taxes, duties and government charges (but specifically excluding any taxes based on net income imposed upon the sale of the PRODUCTS) to the extent included in the gross sales price, wherein rebates, charge-backs, administrative fees and sales or other like taxes are actually paid or incurred by LICENSEE, SUBLCENSEES, REGISTERED AFFILIATES and/or their respective sub-licensees. A sale of the Product to third party customers shall also include a transfer or other disposition for consideration other than case, in which case such consideration shall be valued at the fair market value thereof.

 

  1.13. NON-APPROVED COUNTRIES means any countries other than APPROVED COUNTRIES.

 

  1.14. PACKAGING CELLS means PER.C6® CELLS and MODIFIED CELLS.

 

  1.15.

PACKAGING CELL-EXPRESSION SEQUENCE means (i) any recombinant DNA sequence used by LICENSEE, or expression product or any alteration or modification

 

2

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  thereof, derived from or obtained by, or produced using PACKAGING CELLS; or (ii) a fragment of any recombinant DNA sequence or expression product derived from obtained by, or produced using PACKAGING CELLS, and (iii) provided that (i) and (ii) are based upon and/or are derived from VBL TECHNOLOGY in combination with the genome of a serotype 5 human adenovirus.

 

  1.16. PACKAGING CELL KNOW HOW means PER.C6® KNOW HOW, MODIFIED CELLS and all materials, information, experience and data, formulae, procedures, results and specifications, regulatory filings and clinical and pre-clinical data, in written or electronic form, which are specifically related to MODIFIED CELLS, which (i) are in the possession of the Parties at the EFFECTIVE DATE or come into the possession of the Parties during the TERM of this Agreement, (ii) are not generally known (iii) are necessary for the research use of the MODIFIED CELLS, and (iv) are not subject to a third party confidentiality obligation that prevents either Party from disclosing the same.

 

  1.17. PATENT means granted patents, including utility models and certificates of I vention, and reissues, reexaminations, supplementary protection certificates, extensions, and term restorations thereof, and patent applications therefor, including any continuations, continuations-in-parts, and/or divisionals applications thereof, and any and all patents issuing from any of the above.

 

  1.18. PER.C6® CELL LINE or PER.C6® CELL means the cells deposited under ECACC No. 96022940, as described in Exhibit 1.15, as updated by CRUCELL from time to time in accordance with Section 3 below to include additional CELLS deposited following the EFFECTIVE DATE.

 

  1.19. PER.C6® KNOW HOW means PER.C6® CELLS and all materials, information, experience and data, formulae, procedures, processes and techniques, results and specifications, know-how, regulatory filings and clinical and pre-clinical data, which are specifically related to PER.C6® CELLS, and which are described in the PER.C6® KNOW HOW FILE, as updated by CRUCELL from time to time in accordance with Section 3 below.

 

  1.20. PER.C6® KNOW HOW FILE means the written compilation of PER.C6® KNOW HOW and PACKAGING CELL KNOW HOW, which is provided to all PER.C6® licensees, and which includes but it not limited to processing and manufacturing information and data limited to using PER.C6® CELLS and/or MODIFIED CELLS for the production of replication defective adenoviral vectors therewith.

 

  1.21. PER.C6® PATENTS mean PATENTS that CRUCELL owns, or controls by license or otherwise, wherein said license has a sublicense right, or which CRUCELL has a right to assignment, and that claim PER.C6® CELLS or the use thereof for the manufacture of replication defective adenoviral vectors, identified on Exhibit 1.21.

 

  1.22. PRODUCT means a pharmaceutical product, intended for administration to human subjects, comprising of PACKAGING CELL-EXPRESSION SEQUENCE, in final finished form.

 

  1.23. PROGRAMS means research and development programs of LICENSEE or its SUBLICENSEES in the FIELD to develop PRODUCT in the FIELD, including but not limited to any and all pre-market-registration activities and post-market-approval studies.

 

  1.24. REGISTERED AFFILIATE means an AFFILIATE operating in APPROVED COUNTRIES to the extent identified in Exhibit 1.24 from time to time in accordance with the provisions of Section 2.1.5 below, providing full details of the name, offices and branches of such AFFILIATE or STRATEGIC PARTNER.

 

3

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  1.25. STRATEGIC PARTNER means a reputable company with whom VBL has entered into a collaboration agreement for the co-development and / or co-marketing of pharmaceutical products, substantially discovered, researched or developed by VBL in the FIELD which either (i) enters into a material transfer agreement with CRUCELL substantially in the form of Exhibit 1.25 hereto, or (ii) does not obtain access to the PACKAGING CELLS.

 

  1.26. SUBLICENSEE means a REGISTERED AFFILIATE to which LICENSEE grants a sublicense under and in accordance with this Agreement.

 

  1.27. TERM starts on the EFFECTIVE DATE and continues as described in Section 7.1.

 

  1.28. THIRD PARTIES means any person or entity other than VBL, CRUCELL, SUBLICENSEES, AFFILIATES or STRATEGIC PARTNER.

 

  1.29. VALID PATENT CLAIM shall mean a claim in any issued and unexpired PER.C6® PATENT, which claim has not been held invalid by a non-appealed or unappealable decision by a court or other appropriate body of competent jurisdiction, provided, however, that there exists no outstanding order, injunction or other action (including any temporary relief) that impairs the rights granted under such CLAIM by LICENSEE, its SUBLICENSEES or REGISTERED AFFILIATES, as contemplated under this Agreement. For the purpose of royalty determination and payment, any claim being prosecuted in a pending patent application in a particular country shall be deemed to be a VALID PATENT CLAIM provided such claim is not pending for more than ten (10) years from the earliest filing date to which the patent application is entitled to claim in such country (such as the first filed application based on a PCT application and claiming the PCT filing date, or the first national patent application from which subsequent patent applications claim filing date benefit) and in which case it shall cease to be considered a VALID PATENT CLAIM until a patent in the pertinent country based on such application is granted.

 

  1.30. VTS™ TECHNOLOGY means LICENSEE’s proprietary VTS™ (Vascular Targeting System) platform technology that enables control of gene expression to areas in which angiogenesis is taking place to either promote or destroy newly formed blood vessels.

 

  1.31. VBL PROPRIETARY RIGHTS shall mean, as between the Parties, all right and title in and to VBL TECHNOLOGY, LICENSEE’S INFORMATION, PACKAGING CELL-EXPRESSION SEQUENCE and PRODUCTS, including without limitation (i) all data, results, inventions, know-how, improvements, developments or other information arising from or in connection with the PROGRAM; and (ii) any applications, improvements, modifications and derivatives of any of the above and any know-how, proprietary rights and PATENTS relating thereto or arising therefrom.

 

  1.32 VBL TECHNOLOGY shall mean, as between the Parties, replication-deficient E1-and E3-deleted adenoviral 5 vector or adenovirus 3 vector and conditionally replicative adenovirus (CRAD) 3 and 5 Vector, containing either the FAS-Chimera transgene or Tyrosine Kinase and VTS™ TECHNOLOGY, and any know how related thereto and to the use thereof. At any time during the TERM, LICENSEE may provide CRUCELL with written notice of its wish for the transgene to be changed. Such change shall be deemed effective unless CRUCELL responds to LICENSEE’s notice within thirty (30) days of its receipt that is withholding consent, provided such consent may only be withheld if such change would result in a technology which is either (i) directly competitive with another technolofy under a then existing exclusive out-license by CRUCELL, or (ii) infringes any CRUCELL’s patent which are not otherwise covered in this Agreement. For the avoidance of doubt VBL technology will contain only one (1) Transgene in combination with aforementioned either Adenovirus 3 or 5 or (CRAD) and VTS™ TECHNOLOGY.

 

4

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

2. LICENSES; SUBLICENSING; OWNERSHIP OF CERTAIN RIGHTS; GRANT BACK LICENSE

 

  2.1. CRUCELL Grant to LICENSEE.

 

  2.1.1. CRUCELL hereby grants to LICENSEE, a non-exclusive, worldwide license, under the PER.C6® PATENTS and PER.C6® KNOW HOW, without the right to grant sublicenses except to SUBLICENSEES in accordance with the provisions of Section 2.1.4 below, (1) to use and import PER.C6® CELLS and PER.C6® KNOW HOW for the sole purpose of making MODIFIED CELLS during the course and performance of PROGRAMS; and (2) to use and import MODIFIED CELLS and PACKAGING CELL KNOW HOW during the course and performance of PROGRAMS; and (3) to use and import PACKAGING CELLS and PACKAGING CELL KNOW HOW to manufacture and to have made, in facilities of LICENSEE or its SUBLICENSEES subject to Section 2.4 below, PRODUCTS for use in the FIELD. For the avoidance of doubt, and subject to such third party entering first into a Material Transfer Agreement with CRUCELL prior to the transfer of any PACKAGING CELLS or PACKAGING CELL KNOW HOW, LICENSEE is also granted hereunder the right to provide PACKAGING CELLS, PACKAGING CELL KNOW-HOW and PRODUCTS to third parties for bona fide contract service purposes in the course and performance of PROGRAMS and for the manufacture and making of PRODUCTS solely on LICENSEES’ behalf.

 

  2.1.2. CRUCELL hereby grants to LICENSEE, a non-exclusive, worldwide license, under the PER.C6® PATENTS and PER.C6® KNOW HOW, with the right to grant sublicenses, to develop, use, import, offer to sell, and sell PRODUCTS for use in the FIELD.

 

  2.1.3. Sublicense Requirements in General. Any agreement in which LICENSEE purports to sublicense the rights granted herein under the PER.C6® PATENTS and PER.C6® KNOW HOW, (i) shall not grant any further right to sublicense under the PER.C6® PATENTS and PER.C6® KNOW HOW nor grant any right to transfer the PER.C6® KNOW HOW or the sublicensed rights; and (ii) shall include terms at least as restrictive as those contained in this Agreement with respect to the use and exploitation of the rights granted under the PER.C6® PATENTS and PER.C6® KNOW HOW.

 

  2.1.4.

Certain Sublicense Requirements – REGISTERED AFFILIATES. LICENSEE shall be permitted to sublicense its rights and obligations pursuant to Section 2.1.1 to REGISTERED AFFILIATES (without the right to further sublicense), provided each such REGISTERED AFFILIATE acknowledges and assumes all of the rights, restrictions and obligations of this Agreement applicable to such SUBLICENSEE hereunder, except, as between the Parties, for those rights and obligations for which LICENSEE shall be solely responsible as provided for herein (e.g. indicated by wording such as “on its own behalf and on behalf of its SUBLICENSEES”), in a writing signed by a duly authorized representative of such REGISTERED AFFILIATE. LICENSEE shall be responsible for assuring that each REGISTERED AFFILIATE has become fully aware of, and complies with, its rights, restrictions and obligations under this Agreement as a SUBLICENSEE prior to such REGISTERED AFFILIATE exercising any right that LICENSEE may sublicense to such REGISTERED AFFILIATE hereunder. Irrespective of any written sublicense to a REGISTERED AFFILIATE, the exercise of any sublicenseable right hereunder by a REGISTERED

 

5

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  AFFILIATE shall be deemed to bind such REGISTERED AFFILIATE to comply with the applicable restrictions, obligations and duties hereunder, except for those obligations and duties for which LICENSEE is solely responsible as provided herein. Irrespective of the number of SUBLICENSEES, CRUCELL shall only be required to communicate with, and provide technical assistance to, LICENSEE, or one designated SUBLICENSEE, unless the Parties agree otherwise in a written and duly executed amendment hereto. LICENSEE and its REGISTERED AFFILIATES shall be jointly and severally liable towards CRUCELL for their compliance with the restrictions, obligations and duties hereunder.

 

  2.1.5. At any time during the TERM, LICENSEE may provide CRUCELL with written notice of its wish for a new AFFILIATE to become a REGISTERED AFFILIATE. If Parties agree in writing that such AFFILIATE shall become a REGISTERED AFFILIATE, such AFFILIATE shall be included in Exhibit 1.20, by way of a duly executed written amendment, after CRUCELL has received the document duly executed by the respective AFFILIATE as referred to in Section 2.1.4. CRUCELL shall respond to LICENSEE’s notice within fourteen (14) days of its receipt, and shall not unreasonably withhold its consent to the addition of an Affiliate as aforesaid.

 

  2.1.6. The license grant in this Section 2 shall be effective from the date that CRUCELL receives the License Fee specified in Section 4 herein until expiration of the TERM.

 

  2.2. Restricted Access to PACKAGING CELLS

The licenses grant herein is restricted such that LICENSEE and its SUBLICENSEES shall not be permitted under the terms of this Agreement to engage in the following activities:

 

  2.2.1. to use PACKAGING CELLS (i) in or for FUNCTIONAL GENOMICS studies, (ii) for the manufacture of RECOMBINANT PROTEIN, (iii) in or for the manufacture of vaccines against communicable infectious agents, or (iv) in or for the development of products to prevent or treat diseases caused by chicken anemia virus, or to produce vectors, or expression products thereof, containing all or a part of a chicken anemia virus gene;

 

  2.2.2. to use, store, hold or otherwise deliver PACKAGING CELLS or PACKAGING CELL KNOW HOW in or to NON-APPROVED COUNTRIES;

 

  2.2.3. to offer, provide, give access to or to otherwise make available to third parties or to AFFILIATES that are not SUBLICENSEES, PACKAGING CELLS and/or PACKAGING CELLS KNOW HOW, except as provided for in Section 2.3 and 2.4 below;

 

  2.2.4. to offer or provide services to third parties, or to AFFILIATES that are not SUBLICENSEES, relating to or using PACKAGING CELLS and/or PACKAGING CELLS KNOW HOW.

 

  2.3.

Permitted Access to PACKAGING CELLS. Sections 2.2.3 and 2.2.4 shall not apply to the extent that LICENSEE or its REGISTERED AFFILIATES will be required to provide, give access to or otherwise make available, by order or regulation of a governmental agency or court of competent jurisdiction, the results, materials, or know how obtained in the course of PROGRAMS, or

 

6

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  incorporating PACKAGING CELLS or PACKAGING CELL KNOW HOW, or the sale and/or distribution of PRODUCTS. Under such circumstances, LICENSEE shall promptly notify CRUCELL of such order or regulation requiring disclosure and shall make its best efforts to cooperate with CRUCELL to preserve the confidentiality of, and CRUCELL’s proprietary interest in, the PACKAGING CELL KNOW HOW.

 

  2.4. Supply of PACKAGING CELLS to Contractors.

 

  2.4.1. Subject to the conditions stated in this Section, LICENSEE shall have the right to deliver to a fee-for-service contractor (“Contractor”), PACKAGING CELLS and PACKAGING CELL KNOW HOW (1) to conduct authorized studies of and other tasks relating to PACKAGING CELLS, solely for use by LICENSEE in PROGRAMS, and/or (2) to use PACKAGING CELLS and PACKAGING CELL KNOW HOW to develop processes and perform other tasks for the manufacture and making of, and to manufacture and make, PACKAGING CELLS and PRODUCTS. LICENSEE shall not provide PACKAGING CELLS or PACKAGING CELL KNOW HOW to a fee-for-service Contractor except pursuant to a completely executed, written PER.C6® Material Transfer Agreement (“MTA”) with CRUCELL. The Contractor shall enter into a material transfer agreement substantially in the form of Exhibit 2.4.1 hereto.

 

  2.4.2. CRUCELL shall have the right to disapprove the choice of any fee-for-service third party that is not reputable and/or reliable or operates in a NON-APPROVED COUNTRY, which disapproval shall only be asserted reasonably and upon prompt notice to LICENSEE of no later than fourteen (14) days following receipt of such Contractor’s details with reference specifically to this section, setting forth the reasons for CRUCELL’S disapproval. For purposes of this Section 2.4.2, “not reputable and/or reliable” shall mean, by way of example, that such fee-for-service third party is located in a country or jurisdiction where CRUCELL has reason to believe in good faith (a) does not provide adequate protection for intellectual property and proprietary information or (b) does not provide adequate judicial recourse in case of misappropriation or misuse of intellectual property or proprietary information. Countries or jurisdictions that are on the U.S. Trade Representative’s annual “Special 301” Watch List shall be deemed to qualify as countries or jurisdictions that do not provide adequate protection or recourse as referred to under (i)(a) and (i)(b) above. CRUCELL has pre-approved on Exhibit 2.4.2 the third party contractors listed therein.

 

  2.5. Ownership of Certain Rights; Grant Back License

 

  2.5.1. Except where expressly stated otherwise in this Agreement to the contrary, CRUCELL shall have no right, title and interest in and to any VBL PROPRIETARY RIGHTS (including any right to be notified thereof), provided that LICENSEE may notify CRUCELL of such information from time to time, at its sole discretion.

 

  2.5.2.

LICENSEE and its REGISTERED AFFILIATES hereby agree to grant to CRUCELL a perpetual, royalty-free, non-exclusive worldwide license, with the right to sublicense, under the IMPROVEMENT PATENT RIGHTS and IMPROVEMENT KNOW HOW RIGHTS, provided that the license right under this Section shall not extend to the manufacture, use or sale of the particular PACKAGING

 

7

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  CELLEXPRESSION SEQUENCE(S) and/or PRODUCT(S) or the VBL Technology that are developed by LICENSEE or its SUBLICENSEES and that are the subject of this Agreement or the VBL PROPRIETARY RIGHTS.

 

3. SUPPLY OF CELLS AND KNOW-HOW; CERTAIN UPDATES; TECHNICAL ASSISTANCE; REPORTING

 

  3.1. Supply of Cells and Know-How. Within thirty (30) days after receipt of the License Issuance Fee payment under Section 4.1.1, CRUCELL shall disclose and transfer to LICENSEE PER.C6® CELLS and the PER.C6® KNOW HOW that is incorporated into the most recent version of the PER.C6® KNOW HOW FILE.

 

  3.2. Updates. During the TERM, CRUCELL shall promptly provide updates (i) of the PER.C6® KNOW HOW FILE to LICENSEE as it is revised and made available to all or substantially all PER.C6® licensees or to PER.C6® licensees conducting activities or granted rights similar to those contained in this Agreement, including without limitation new uses in the Field of PER.C6® CELLS and KNOW HOW, improved and updated techniques and know-how for the use of PER.C6® CELLS and PER.C6® LOW HOW, and any known problems relating to the use of PER.C6® CELLS and PER.C6® KNOW HOW or deviations from previously provided information, all as may be applicable to the license granted to LICENSEE hereunder and (ii) of any safety or regulatory concerns that come to CRUCELL’s attention relating to the PACKAGING CELL and PACKAGING CELL KNOW HOW.

 

  3.3. Technical Assistance. During the TERM, CRUCELL shall provide reasonable technical assistance (including guidance on know how related to the work with the PER.C6® CELLS) to LICENSEE, as may be necessary to use PACKAGING CELLS and PACKAGING CELL KNOW HOW in PROGRAMS, upon reasonable request and free of any additional cost to LICENSEE. To support the KNOW HOW transfer, LICENSEE shall be entitled, upon reasonable notice to CRUCELL, to visit CRUCELL’s facilities from time to time, but no more than five (5) days, once a year and view the production of the PER.C6® CELLS and other relevant processes and techniques relating to the making of MODIFIED CELLS, as well as to receive answers from CRUCELL’s employees regarding the use of such cells and of the PACKAGING CELL KNOW HOW, to the extent necessary for the purposes of a PROGRAM. LICENSEE shall compensate CRUCELL for technical assistance in excess of two (2) man-day visits by CRUCELL technical personnel to LICENSEE’s facilities, on an annual basis, for the first two (2) years of the TERM, on reasonable terms to be agreed in advance. A third man-day visit (or more) shall be at no additional cost if LICENSEE reports a material deviation from established PER.C6 KNOW HOW performance parameters, which deviation report requires such third man-day of technical assistance.

 

  3.4. Access and Reference to BMF; Conduct of Registration and Testing.

 

  3.4.1.

LICENSEE and its REGISTERED AFFILIATES acknowledge that the BMF is owned by CRUCELL, may be filed by CRUCELL with other foreign governmental equivalent to the FDA and is confidential and of crucial importance to the Parties as well as to all other licensees of PER.C6® CELL technology. LICENSEE and its REGISTERED AFFILIATES shall have the right to review CRUCELL’s copy of the BMF filed with the FDA and other Governmental Authorities after providing CRUCELL with thirty (30) days prior notice. LICENSEE has the right to cross-reference the BMF as may be required for any regulatory submissions to Governmental Authorities, and upon

 

8

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  LICENSEE’ request CRUCELL shall (i) notify the FDA (with a copy to LICENSEE) that LICENSEE is authorized to reference the data within the BMF; and (ii) provide LICENSEE with any and all existing BMF documentation in the possession of CRUCELL (provided that CRUCELL is legally able to do so) in so far required to support any regulatory submission LICENSEE makes to a Governmental Authority in a country where a BMF or its foreign equivalent has not been submitted or is not in effect or may not be referenced to. CRUCELL shall notify LICENSEE of any significant update to the BMF from time to time and shall provide LICENSEE with a copy thereof upon its request as set forth above.

 

  3.4.2. LICENSEE and its REGISTERED AFFILIATES shall not be entitled to, and agree that they will not, characterize, or issue releases or certificates of analysis for, or analyze the genome of, any PACKAGING CELLS, or engage in any research of PACKAGING CELLS that concern any safety, toxicity or tumorgenicity of PACKAGING CELLS without obtaining the prior written agreement of CRUCELL, provided that, if any Governmental Authority requests additional data or characterization of PACKAGING CELLS that CRUCELL chooses not to provide LICENSEE shall have the right to perform its own studies solely as required by the Governmental Authority, and to provide the results to the requesting Governmental Authority. Failure by CRUCELL to provide LICENSEE with such information or data for delivery to the applicable Governmental Authority within a reasonable period shall be deemed as CRUCELL choosing not to provide same. The aforementioned restrictions shall only apply with respect to PACKAGING CELLS, and not PACKAGING CELL-EXPRESSION SEQUENCE or PRODUCT, the analysis of which shall be at the sole discretion of LICENSEE and not subject to any approval of CRUCELL.

 

  3.4.3. LICENSEE further agrees to use its reasonable efforts to promptly notify CRUCELL of any and all communications to and from Governmental Authorities directly relating to the safety of PACKAGING CELLS and agrees to consult promptly with CRUCELL to resolve any such concerns with the FDA or such other Governmental Authorities, Noncompliance by LICENSEE with the obligation to use its reasonable efforts to obtain prior agreement of CRUCELL prior to any characterization, release or certificate issuances of PACKAGING CELLS as set forth in Section 3.4.2 above, or to promptly notify and consult with CRUCELL in its efforts to resolve any such issues with the FDA or other Governmental Authorities as set forth in this Section 3.4.3 shall be considered to constitute a failure to comply with a material condition or covenant of this Agreement to which Section 6.5 herein applies.

 

  3.5. Reporting.

 

  3.5.1. LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall keep CRUCELL informed on a bi-yearly (six(6)-month) basis about (1) any communication with Regulatory Authorities about PACKAGING CELLS, and (2) results of any testing performed on the PACKAGING CELLS. A template for use in complying with the quarterly reporting obligation is attached as Exhibit 3.5.1.

 

  3.5.2.

LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall keep CRUCELL informed on an annual basis, on or before the anniversary of the EFFECTIVE DATE, with a detailed report of the

 

9

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  data relating specifically to PACKAGING CELL performance, PACKAGING CELL KNOW HOW, as well as the operating, culturing and manufacturing parameters and data resulting from its use of the PACKAGING CELL during the course of the PROGRAM. To facilitate the mutually beneficial resolution of any PACKAGING CELL technical performance issue, if any, LICENSEE hereby agrees to discuss with CRUCELL technical personnel relevant technical data to assist in resolving such issues. A template for use in complying with the annual reporting obligation is attached as Exhibit 3.5.2.

 

  3.5.3. It is agreed and understood that LICENSEE shall not be obligated to disclose any information, data or know-how relating to VBL PROPRIETARY RIGHTS unless and to the extent it is related to PACKAGING CELLS and/or their use hereunder. In such event, any and all disclosed information, data or know-how shall not be used or disclosed without LICENSEE’s prior written consent, which consent may be withheld at its sole discretion.

 

  3.5.4. LICENSEE, on its own behalf and on behalf of its SUBLICENSEES, shall promptly notify CRUCELL in writing of any substantial deviations from established PER.C6® CELL characteristics and/or performance parameters included in PER.C6® KNOW HOW, prior to any notification by LICENSEE or its SUBLICENSEES to any other entity other than to the appropriate Regulatory Authorities such as the FDA.

 

  3.5.5. Subject to the provisions of Section 3.5.3, information reported to CRUCELL pursuant to Sections 3.5.1 through 3.5.4 may be used by CRUCELL to assist LICENSEE in the successful implementation of PACKAGING CELL KNOW HOW, resolving technical and regulatory issues respecting PACKAGING CELL and the BMF, to amend and/or annotate the collection of PER.C6® KNOW HOW for delivery to PER.C6® licensees and/or to update the BMF, which PER.C6® KNOW HOW and BMF shall only be disclosed under conditions of confidentiality. Except as expressly in Sections 2.5.2, 2.5.3 and 2.5.4 above, CRUCELL shall not use any information or know-how relating to PRODUCT(S) or PACKAGING CELL EXPRESSION SEQUENCE(S) that are developed by LICENSEE or its SUBLICENSEES, or relating to any VBL PROPRIETARY RIGHTS, nor disclose any of the above to any licensee or other third party (including any Regulatory Authority) without the prior written consent of LICENSEE, which consent may be withheld at its sole discretion.

 

4. LICENSE FEES

 

  4.1. License Fees. In consideration of the licenses granted and the PER.C6® KNOW HOW supplied hereunder, LICENSEE shall pay the following amounts to CRUCELL during the TERM:

 

  4.1.1. Within ten (10) days from the EFFECTIVE DATE, a License Issuance Fee of € 75,000 (seventy-five thousand Euros), exclusive of V.A.T.; and

 

  4.1.2. Starting on the first anniversary date of the EFFECTIVE DATE (TBD when the first anniversary date should start, since we are already paying an annual fee with a different anniversary date), an Annual License Maintenance Fee of € 100,000 (one hundred thousand Euros), exclusive of V.A.T., to be paid in arrears.

 

10

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  4.2. Development Milestone Payments: LICENSEE shall pay CRUCELL non-creditable and non-refundable payments of € 400,000 (four hundred thousand Euros), exclusive of V.A.T., with respect to each PRODUCT for which a governmental health regulatory authority grants marketing approval, within thirty (30) days of the issuance of the first regulatory marketing approval letter from such governmental health regulatory authority for the first indication for each such PRODUCT. Payment under this Section 4.2 shall be made once for each unique PRODUCT.

 

  4.3. Running Royalty. LICENSEE shall pay to CRUCELL a running royalty (the “Running Royalty”) as follows:

 

  4.3.1. If PACKAGING CELLS and/or PACKAGING CELL KNOW-HOW are, or were, used in the development, use, manufacture, importation or sale of the PRODUCT, a Running Royalty of one and half a percent (1.5%) of the NET SALES for the longer of (i) ten (10) years from the FIRST COMMERCIAL SALE of the PRODUCT;

 

  4.3.2. If the use, manufacture, importation or sale of the PRODUCT comes under the scope of at least one VALID PATENT CLAIM, on a country by country basis, a Running Royalty of half a percent (0.5%) of NET SALES.

 

  4.3.3. Only one Running Royalty, that may be either a Know-How Royalty (Section 4.3.1), or a Patent Royalty (Section 4.3.2) or a combination of the Know-How and Patent Royalties (1.5 + 0.5 = 2.0%), shall be due with respect to the same unit of PRODUCT.

 

5. PAYMENTS; BOOKS AND RECORDS

 

  5.1. Royalty Reports and Payments. After the FIRST COMMERCIAL SALE of the PRODUCT on which Running Royalties are required, LICENSEE shall submit quarterly written reports to CRUCELL within ninety (90) days after the end of each calendar quarter, stating in each such report the number, description, and aggregate NET SALES of the PRODUCT sold during the calendar quarter upon which a Running Royalty is payable under Section 4 above. Concurrently with the submission of such reports, LICENSEE shall pay to CRUCELL Running Royalties at the rate specified in Section 4.

 

  5.2. LICENSEE Obligations. LICENSEE shall be solely responsible for the payment to CRUCELL of any royalties, license fees and milestone or other payments due from its AFFILIATES and/or SUBLICENSEES, and for any payments to third parties under licenses or similar agreements between LICENSEE and such third parties necessary to allow the manufacture, use or sale of the PRODUCT by LICENSEE, or SUBLICENSEES;

 

  5.3. Method of Payment.

 

  5.3.1. All payments due hereunder to CRUCELL shall be paid in Euros in immediately available funds, for CRUCELL’s account, to a bank designated in writing by CRUCELL. CRUCELL shall provide LICENSEE with an invoice prior to the due dates specified in Section 4.1.2 and 4.2, and LICENSEE shall pay such invoices within the later of the applicable due date or thirty (30) days of receipt by LICENSEE. If the invoice is received later than the due date, then LICENSEE shall have thirty (30) days from the receipt of the invoice to pay the invoiced amount.

 

  5.3.2.

CRUCELL shall submit an invoice to LICENSEE for all transportation, packing or other documented and reasonable costs incurred on LICENSEE’S benefit and at LICENSEE’S request pursuant to this

 

11

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  Agreement in connection with providing PACKAGING CELL KNOW HOW to LICENSEE. LICENSEE shall pay invoices specifying these reasonable costs within thirty (30) days of receipt.

 

  5.3.3. Inflation Index Adjustment: Commencing from the first (1st) anniversary date of the EFFECTIVE DATE, license fees due under Setion 4.1 shall be increased by two and one half percent (2.5%) upon each anniversary of the EFFFECTIVE DATE until and including the eighth anniversary of the EFFECTIVE DATE.

 

  5.4. Interest. If LICENSEE fails to make any payment under this Agreement within ninety (90) days of the date on which the same becomes due and payable, LICENSEE shall owe CRUCELL interest at the rate of twelve and a half percent (12.5%) per annum (as determined on the date the payment first become due) on any outstanding amount until payment is made in full. If parties are in dispute on the amount of the royalties payable pursuant to Clause 5.1. the penalty becomes due only after Parties have agreed on the exact royalty amount due.

 

  5.5. No Refunds. Payments referred to in this Section 5 shall not be refundable under any circumstances, including but not limited to the termination of this Agreement for whatever reason.

 

  5.6. Currency Conversion. If any currency conversion shall be required in connection with the calculation of royalties hereunder, such conversion shall be made using the following procedures. Sales recorded during a month will be translated to Euro values at the rate on the 1st working day of that month based on the exchange rates published on the OANDA website. Any changes to procedures for currency conversion shall only apply after such notice has been delivered and provided that such changes are consistently applied across LICENSEE’s operating units and continue to maintain a set methodology for currency conversion.

 

  5.7. Withholding Taxes. If LICENSEE is required by any applicable law, rule or regulation to make any deduction or withholding for or on account of any Tax (as defined below) from any payment to be made to CRUCELL under this Agreement, then LICENSEE shall (i) promptly notify CRUCELL of such requirement, (ii) pay to the relevant authorities the full amount required to be deducted or withheld promptly upon determining that such deduction or withholding is required or receiving notice that such amount has been assessed against CRUCELL, and (iii) promptly forward to CRUCELL an official receipt, or certified copy or other documentation reasonably acceptable to CRUCELL, evidencing such payment to such authorities.

 

  5.7.1. If CRUCELL is entitled to an exemption from or reduction of withholding tax under any applicable law or treaty with respect to any payments made hereunder, CRUCELL shall deliver to LICENSEE at the time or times prescribed by applicable law or reasonably requested by LICENSEE, such properly completed and executed documentation prescribed by applicable law as will permit such payments to be made without withholding or at a reduced rate.

 

  5.7.2. For purposes of this Section, the term “Tax” shall mean any present or future tax, levy, impost, duty, charge, assessment or fee of any nature (including interest, penalties and additions thereto) that is imposed by any government or other taxing authority in respect of a payment under this Commercialization Agreement.

 

  5.8.

Records; Inspection. LICENSEE shall and shall cause its REGISTERED AFFILIATES and its SUBLICENSEES shall keep complete, true and accurate

 

12

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  books of account and records for the purpose of determining the Running Royalty amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of LICENSEE, and SUBLICENSEES, as the case may be, for at least three (3) years following the end of the calendar quarter to which they pertain. Such records will be open for inspection during such three (3) year period by an independent public accounting firm of national prominence retained by CRUCELL and acceptable to LICENSEE for the purpose of verifying the Running Royalty statements. Such inspections may be made no more than once each calendar year, at reasonable times mutually agreed to by LICENSEE and CRUCELL. CRUCELL’s representative or agent will be obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this Section shall be at CRUCELL’s expense, unless a variation or error producing an increase exceeding ten percent (10%) of the Running Royalty amount stated for any period covered by the inspection is established in the course of any such inspection, whereupon all reasonable and customary costs relating to the inspection for such period will be paid by LICENSEE.

 

6. TERM AND TERMINATION

 

  6.1. Agreement Term. This Agreement shall become effective as of the EFFECTIVE DATE and, unless earlier terminated pursuant to the other provisions of this Section, shall continue in full force and effect on a country-by-country basis, until LICENSEE has no remaining obligation to pay to CRUCELL the Running Royalty in accordance with Section 4.3. Thereafter, LICENSEE shall have a fully paid up, world wide, royalty free, perpetual license right under the PER.C6® PATENTS and PER.C6® KNOW HOW to continue to make, have made, import, use, offer for sale and sell the PRODUCT(S) in such countries.

 

  6.2. Termination by LICENSEE. LICENSEE may terminate this Agreement by giving CRUCELL three (3) months prior written notice, and payment of all outstanding monies owed to CRUCELL until the date of termination, such as partial payment of arrears obligations pursuant to Section 4.1.2, which payment is due prior to actual termination of the Agreement.

 

  6.3. Termination by Mutual Agreement. This Agreement may be terminated upon mutual written agreement between the Parties.

 

  6.4. Termination Upon Insolvency or Bankruptcy. Either Party may terminate this Agreement, by notice to the other Party with immediate effect, if (a) the other Party (i) pledges substantially all of its assets for the benefit of creditors, and the conditions for the creditors to enforce their rights to control those assets have been satisfied (such as the expiration of a cure period for an uncured default), institutes, consents to or fails to diligently oppose any proceeding seeking to adjudicate it a bankrupt or insolvent or (b) any proceeding is instituted against or in respect of the other Party by third parties seeking bankruptcy relief and such proceeding continues undismissed, or unstayed and in effect for a period of 60 days after the institution thereof.

 

  6.5.

Termination by Default. If either Party defaults in the performance of, or fails to be in compliance with, any material condition or covenant of this Agreement and any such default or noncompliance shall not have been remedied, or steps initiated to remedy the same, to the other Party’s reasonable satisfaction within three (3) months for payment defaults, and within six (6) months for other defaults or non-compliance, after receipt by the defaulting Party of a written notice thereof from the other Party, the Party not in default may, without further notice, forthwith terminate this Agreement at its option, provided however that in the event of breach by CRUCELL, accrual and

 

13

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  payment of any amounts due to it hereunder shall be suspended during the cure period; and provided, further, that in the event of a dispute as to default, non-compliance or right to terminate this Agreement, this Agreement shall continue until such dispute is finally resolved pursuant to Section 10.3 hereof.

 

  6.6. Rights and Obligations on Term, Termination, or Suspension.

 

  6.6.1. Unless expressly provided to the contrary, the following provisions shall survive the termination of this Agreement: Sections 1, 2.3, 2.5, 3.5.4, 3.5.5, 6.6, 6.7, 7, 8, 9 and 10 hereof.

 

  6.6.2. Return of PACKAGING CELL KNOW HOW. Except in the case of termination by LICENSEE for default pursuant to Section 6.5, upon early termination of this Agreement by either Party, at CRUCELL’S written request, LICENSEE and its AFFILIATES shall destroy all supplies of PACKAGING CELL KNOW HOW, and shall promptly thereafter confirm such destruction in writing to CRUCELL, except for one copy of such written information to be retained in confidential files and to be used solely to establish rights and obligations under this Agreement, and for no other use or purpose.

 

  6.7. Termination by either Party pursuant to this Article shall not prejudice any other remedy that a Party might have at law or equity.

 

7. CONFIDENTIALITY

 

  7.1. Confidentiality Obligations. Each Party shall maintain in confidence all information disclosed or otherwise made available by the other which is identified as confidential and which is confirmed in writing and marked “confidential” or otherwise properly labeled as confidential within thirty (30) days of such original disclosure, including without limitations, information relating to PACKAGING CELL KNOW HOW and PROGRAMS or results of PROGRAMS (all such information hereafter referred to as “INFORMATION”), and shall not use such INFORMATION or disclose the same to anyone, except (i) that LICENSEE may disclose CRUCELL’S INFORMATION to its REGISTERED AFFILIATES and SUBLICENSEES, those of its agents, direct employees, consultants and investigators for the execution of PROGRAMS and manufacturing and sale of PRODUCTS, as set out in this Agreement; (ii) that LICENSEE may disclose CRUCELL’S INFORMATION as required to governmental health regulatory authorities; (iii) that CRUCELL may disclose LICENSEE’S INFORMATION to its agents, direct employees, consultants and investigators who have a need-to-know for the performance of this Agreement; the foregoing as permitted by this Agreement and subject to the responsibilities and obligations as set forth in this Agreement. Either Party may disclose the other Party’s INFORMATION to potential investors and/or strategic partners within the course of a good faith due diligence inquiry to the extent relevant for the purpose of the inquiry. The foregoing is subject to the below:

 

  7.1.1. Prior to such permitted disclosure to such LICENSEE REGISTERED AFFILIATES and SUBLICENSEES, Contractors, agents, direct employees, consultants, investigators, potential investors and other financing sources, investment bankers, advisors, attorneys, accountants and strategic investors, disclosure must be subject to the provisions of a confidentiality agreement containing restrictions no less stringent than the obligations in this Section 7.1 as such restrictions apply to LICENSEE, provided that attorneys and accountants shall not be required to execute such agreement if so informed of the confidential obligations hereunder and provided their professional code of conduct requires that such confidentiality obligations be so observed.

 

14

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  7.1.2. Each Party shall use a similar effort to that which it uses to protect its own trade secrets or proprietary information (but that in any event be no less than customary industry standards) to protect the other Party’s INFORMATION and to ensure that its applicable AFFILIATES and SUBLICENSEES and Contractors (if any), agents, direct employees, consultants, investigators, potential investors and strategic investors do not disclose or make any unauthorized use of such INFORMATION. Each Party shall notify the other promptly of its knowledge of any unauthorized use or disclosure of the other’s INFORMATION and enable it to enforce rights against such use or disclosure.

 

  7.2. Exceptions. The confidentiality and non-use obligations under this Agreement shall not apply to the extent that:

 

  7.2.1. the Party who has received the INFORMATION (“RECIPIENT”) is required to disclose information by order or regulation of a governmental agency or court of competent jurisdiction subject to the provisions of Section 7.3.3 below; or

 

  7.2.2. the RECIPIENT can demonstrate that

 

  7.2.2.1. the party who has received the INFORMATION (“RECIPIENT”) is requited to disclose information by order or regulation of a governmental agency to court of competent jurisdiction subject to the provisions of Section 7.3.3 below or;

 

  7.2.2.2. the disclosed INFORMATION is independently developed without use or regard to the INFORMATION (as shown by RECIPIENT’s written records); or

 

  7.2.2.3. the disclosed INFORMATION was lawfully known by RECIPIENT (as shown by its written records) prior to the date of disclosure to RECIPIENT without an obligation of secrecy, from sources legally entitled to disclose the same without an obligation of secrecy or received by RECIPIENT (as shown by its written records) on an unrestricted basis from a source unrelated to any Party to this Agreement and not, to its knowledge, under a duty of confidentiality.

 

  7.3. Publications and Public Announcements:

 

  7.3.1. Each party shall have the right to publish the existence of this Agreement, but not the terms thereof, with the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed.

 

  7.3.2. Any disclosure which is required by law may be made without the prior consent of the other Party, although the other Party shall be given prompt notice of any such legally required disclosure and an opportunity to comment on, and attempt to challenge or limit the proposed disclosure reasonably in advance to the extent feasible.

 

  7.3.3. Furthermore, the disclosing Party shall make diligent efforts to limit the nature and scope of any disclosure to the extent reasonably possible and to otherwise prevent the disclosure of the non-disclosing Party’s INFORMATION.

 

15

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

8. PATENTS

 

  8.1. CRUCELL shall be responsible and use commercially reasonable efforts for the prosecution, protection and maintenance of PER.C6® PATENTS throughout the TERM, and shall bear all costs, fees and expenses in connection thereto.

 

  8.2. If either Party after the EFFECTIVE DATE is warned or sued by a third party alleging or charging infringement of any patents or published patent applications or any other rights, due to or in connection with the use of PACKAGING CELLS, by either Party, the Party which is warned or sued, shall notify promptly the other Party.

 

  8.3. CRUCELL shall be responsible, at its expense, for settling and/or defending any warning or litigation for patent infringement in which the alleged infringing process or product giving rise to liability for damages involves or arises from use by CRUCELL of PACKAGING CELLS or the practice of any of the PACKAGING CELLS, PER.C6® PATENTS or PACKAGING CELL KNOW-HOW.

In so far as any such infringement action, or the settlement or defense thereof, might have an effect on LICENSEE activities, CRUCELL shall promptly inform LICENSEE of such claim and (i) CRUCELL and LICENSEE shall confer as to any modification of any right granted to LICENSEE hereunder, provided, that such modification shall not substantially alter LICENSEE’s rights hereunder; (ii) LICENSEE shall be entitiled, but shall not be obligated, to attempt to obtain a license from such third party for the right to use such third party’s patent or other applicable right and (iii) in the event that LICENSEE is named thereunder, it shall have the right to participate in the defense of such claim. In any event, if such infringement action might have an effect on LICENSEE activities (i) upon CRUCELL’s written request, LICENSEE agrees to reasonably assist CRUCELL in any such defense; and (ii) LICENSEE shall be entitled to immediately terminate this Agreement.

If LICENSEE should suffer any out of pocket costs and other expenses, including reasonable attorney’s fees, as a result of the assistance in such dispute, CRUCELL shall reimburse LICENSEE such out of pocket costs and expenses incurred by LICENSEE.

LICENSEE shall be responsible, at its expense, for settling and/or defending any warning or litigation for patent infringement made against CRUCELL, in which the alleged infringing process or product giving rise to liability for damages involves use by LICENSEE of PACKAGING CELLS, other than as set forth in Section 8.3 above. If CRUCELL should suffer any damages, losses, out of pocket costs and other expenses and liabilities as a result of such dispute, including reasonable attorney’s fees and payments of royalties to third parties, LICENSEE shall indemnify CRUCELL and it AFFILIATES and hold them harmless against any such expenses and liabilities.

 

  8.4. No Party shall enter into any settlement which admits or concedes that any aspect of the PATENT or know how of the other Party is invalid or unenforceable in any way, without the prior written consent of such other Party.

 

9. REPRESENTATIONS; WARRANTY, INDEMNIFICATION

 

  9.1.

CRUCELL Representations and Warranties. CRUCELL represents and warrants that (a) CRUCELL has the full legal right to enter in this Agreement and to perform its obligations thereunder; (b) CRUCELL will not be violating any law, regulation, order or contractual or other obligations of or applicable to CRUCELL or to the PER.C6® CELLS, PER.C6® PATENTS or PER.C6® KNOW-HOW by executing, delivering or performing this Agreement, and neither the execution or delivery of this Agreement shall not conflict with or violate any

 

16

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  such law, regulation, order or contractual or other obligation; (c) CRUCELL has duly executed and delivered this Agreement, which constitutes a legal valid and binding obligation of CRUCELL, enforceable against CRUCELL in accordance with its terms; (d) CRUCELL is the legal owner of all rights and title in and to the PER.C6® CELLS, PER.C6® PATENTS and PER.C6® KNOW HOW licensed hereunder, free and clear of any encumbrance, charge or restriction, and has the right to grant LICENSEE the licenses granted under this Agreement without conflicting with any third party rights and without creating any encumbrance, charge or restriction in connection therewith; (e) the PER.C6® CELLS provided to LICENSEE or to a designated contractor under 2.1.4 (i) comply with the certificates of analysis that accompany the cells, (ii) comply with the specifications as set forth in the Exhibits hereto, and (iii) have been manufactured, tested and maintained according to the current ICH, FDA and EMEA guidelines; (f) the terms of this Agreement do not create a conflict with or result in the breach of any right, obligation or agreement that CRUCELL has with any third party; (g) it has not received any communication alleging that the PER.C6® CELLS infringes the intellectual property rights of any third party; and (h) CRUCELL will prosecute, maintain and take other actions necessary, in the course of its exercise of good business judgment, to support the continued validity and enforceability of the PER.C6® PATENTS during the term. UNLESS OTHERWISE EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, CRUCELL DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, FITNESS FOR ANY PARTICULAR PURPOSE, RESPECTING ANY MATERIALS PROVIDED TO LICENSEE PURSUANT TO, OR IN ASSOCIATION WITH THE PERFORMANCE OF THIS AGREEMENT, INCLUDING ANY WARRANTIES CONCERNING THE INHERENT PROPERTIES OF PACKAGING CELLS SUPPLIED UNDER THIS AGREEMENT. CRUCELL MAKES NO WARRANTY AS TO THE MERCHANTABILITY OF THE PRODUCTS, PER.C6® KNOW HOW OR PER.C6® PATENTS.

 

  9.2. LICENSEE Warranties. LICENSEE (a) is entitled to enter in this Agreement and to perform its obligations thereunder; (b) LICENSEE does not violate any law, regulation, order or its existing contractual obligations by executing, delivering and performing this Agreement; and (c) LICENSEE has duly executed this Agreement, which constitutes a legal valid and binding obligation of LICENSEE, enforceable against LICENSEE in accordance with its terms.

 

  9.3. Product Liability and Indemnification. CRUCELL shall not be liable for and LICENSEE shall indemnify CRUCELL and hold CRUCELL harmless against any and all liabilities (including product liability), damages, losses or injury, death, costs and expenses, including reasonable attorney’s fees, arising in any manner from the use by LICENSEE or its AFFILIATES of PACKAGING CELLS and/or the PACKAGING CELL KNOW HOW, or the use of any PRODUCT by any human being, regardless of whether such use was contemplated by the Parties, except to the extent such liabilities result from (i) the willful misconduct, gross negligence or written instructions of CRUCELL; and/or pursuant to Section 8.3 above; and/or (iii) any breach of this Agreement by CRUCELL. CRUCELL shall hold harmless LICENSEE and its AFFILIATES against losses arising from the events set forth in clauses (i) and (ii) immediately above.

 

10. MISCELLANEOUS/ RULES OF CONSTRUCTION

 

  10.1. Amendment. This Agreement may not be changed, modified, amended, or supplemented except by a written instrument signed by authorized representatives of both Parties hereto.

 

17

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  10.2. Assignability. LICENSEE’s rights and obligations in this Agreement may not be assigned without the prior written consent of CRUCELL, except to an AFFILIATE, or in the event of a merger or sale of all, or substantially all, of LICENSEE’s assets relating to the subject matter of this Agreement to an assignee, provided that LICENSEE shall remain joint and severally liable with any such assignee for the performance of its assigned obligations hereunder if LICENSEE continues to conduct business following such merger or sale. Such assignment shall then be binding upon, inure to the benefit of the Parties, and be enforceable. Any attempted assignment contrary to the terms of this provision shall be void.

 

  10.3. Choice of Law and Dispute Resolution. This Agreement shall be governed by and construed under the laws of the Netherlands. If any dispute arises out of this Agreement, the Parties will themselves endeavor to settle such dispute amicably. If the Parties fail to arbitration before a single arbitrator, such arbitration to be held in accordance with the rules of arbitration of the International Chamber of Commerce and to be held in The Hague, Netherlands. The Parties shall use good faith efforts to expedite the arbitration. The parties agree that any judgment of the foregoing arbitrator shall be final and binding and shall be enforceable in any competent court having jurisdiction over the adjudged party. Nothing herein shall prevent either party from seeking injunctive relief or other equitable remedies in or out of law.

 

  10.4. Expenses. Each Party shall bear its own expenses, if not expressly agreed otherwise in this Agreement.

 

  10.5. Force Majeure. Neither LICENSEE nor CRUCELL shall be liable for any failure or delay in performance under this Agreement which is due in whole or in part directly or indirectly to any cause of any nature beyond the reasonable control of such Party.

 

  10.6. Further Assurances. Each Party hereto agrees to execute, acknowledge and/or deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

  10.7. Notice and Reports. All notices required by this Agreement shall be in writing. All notices and reports shall be sent by fax followed by registered airmail to the Parties at the following addresses or such other addresses as may be designated in writing by the respective Parties:

 

To CRUCELL:

  

CRUCELL HOLLAND B.V.

Archimedesweg 4

P.O. Box 2048

2301 CA Leiden

THE NETHERLANDS

Attn. Business Development

FAX: +31-71-5248702

 

To LICENSEE:

  

VASCULAR BIOGENICS Ltd.

6 Jonathan Netanyahu Street,

60376, Or-Yehuda,

ISRAEL

Attn. Emmanuel Elalouf

VP Business Development

FAX: 972-3-6346449

Any notices shall be deemed given when received by the other Party.

 

18

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  10.8. Relationships of the Parties. Both Parties are independent contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute CRUCELL and LICENSEE as agents, partners or joint ventures with respect to this Agreement. Neither Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any other contract, agreement, or undertaking with any third party.

 

  10.9. Rules Of Construction.

 

  10.9.1. Captions. Paragraph captions are inserted for convenience only and in no way are to be construed to define, limit or affect the construction or interpretation hereof.

 

  10.9.2. Entire Agreement. This Agreement contains the entire agreement of the Parties regarding the subject matter hereof, and supersedes all prior agreements, understandings, and negotiations between the Parties regarding the same.

 

  10.9.3. “Including”. The words “include”, “including” or “included” are used to indicate that the matters listed are not a complete enumeration of all matters covered and should be read such as “including but not limited to”.

 

  10.9.4. Singular, Plural, Gender. Words denoting the singular, shall include the plural and vice versa. Words denoting one gender shall include all others.

 

  10.9.5. Severability. If any part of this Agreement shall be held invalid and/or unenforceable, the remaining provisions of this Agreement shall nevertheless remain in full force and effect provided that such provisions will permit the transaction contemplated herein to take place in substantially the same manner as originally contemplated by the Parties.

 

  10.9.6. Translations. This Agreement has been written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement. In the event of any conflict in interpretation between the English version and such translation of this Agreement, the English version shall prevail.

 

  10.9.7. Waiver. The waiver by either Party of a breach of any provisions contained herein shall be in writing and shall in no way be construed as a waiver of any prior or succeeding breach of such provision or the waiver of the provision itself.

 

  10.9.8. Trademarks. PER.C6® is a registered trademark of CRUCELL. All right title and interest therein shall remain with CRUCELL. CRUCELL is solely entitled to all goodwill accruing in the trademark PER.C6® as a consequence of the use thereof by LICENSEE or otherwise. LICENSEE may only use CRUCELL’s PER.C6® trademark upon the execution of a separate trademark license agreement with CRUCELL. Not withstanding the aforementioned, for the avoidance of doubt LICENSEE can use the PER.C6® trademark for reference purposes in connection with research publications as well as regulatory filings.

 

  10.9.9.

Use of Party’s Name. No right, express or implied, is granted by tHIS AGREement to LICENSEE to use in any manner other than for regulatory submission purposes the name “CRUCELL” or “INTROGENE”, or to CRUCELL to use in any manner the name of LICENSEE or its Affiliates, or any other trade name, logo or

 

19

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  trademark of the other party in connection with the performance of this Agreement without prior permission from such other party except as elsewhere permitted under this Agreement.

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement to be effective as of the date the last Party signs below.

 

VASCULAR BIOGENICS LTD.     CRUCELL HOLLAND B.V.
      For and on behalf of Crucell N.V.
By:  

/s/ Dror Harats            

    By:  

/s/ [Illegible]

        Crucell NV, represented by
Or Yehuda, April 14, 2011       Leiden April 13, 2011

 

20

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Exhibit 1.18 — Cell Line Designation: PER.C6®

Origin of the Cell Line

PER.C6® cells are [***] transformed with [***] of [***] The estimated copy number is [***] The [***] in the construct is driven by the [***] The [***] are derived from [***]

Cell Line Passage History

Research Master Cell Bank [***] was stored at passage number [***] on 17 January 1996. Research Working Cell Bank [***] was generated from [***] and stored at passage number [***] on 7 February 1996. The cell banks are stored in the [***] of [***] at [***] in [***]

Components Used For Culture of the Cells

[***] with [***] and, optionally, [***]. [***] was used for [***]

Quality Control

All work on the development of PER.C6® cells carried out at Crucell Holland has been carried out under controlled conditions. The data have been reviewed by QA Crucell Holland. The research Master Cell Bank and research Working Cell Bank have been tested by GLP-inspected contract testing companies. All recorded data mentioned have been reviewed by Quality Assurance, Crucell Holland BV, Leiden. All final reports have been reviewed for compliance to the specifications and pertinent relevant regulatory requirements from the US and EEC.

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Safety Tests on the PER.C6® Human Adenoviral Packaging cell Line

Research Master Cell Bank

 

Test

  

Result

[***]

   [***]

Research Working Cell Bank

 

Test

  

Result

[***]

   [***]

 

22

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Exhibit 1.2 – APPROVED COUNTRIES

United States of America

Canada

The member states of the European Union on the EFFECTIVE DATE

Israel

Japan

Australia

New Zealand

 

23

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Exhibit 1.21 – PER.C6® Patents

National patents corresponding to [***] ([***]; [***], [***]). The currently filed members of patent family [***] claim priorities based on European priority documents [***] ([***]) and [***] ([***]). Members of this patent (application) family further include:

 

Applications

  

Filing Date

  

Published

  

Publication

[***]    [***]    [***]    [***]

 

Patents

  

Issue date

         
[***]    [***]      

2. Claims covering the PACKAGING CELLS and the use thereof, excluding claims specifically directed to [***], [***] complementing cells and vectors, in all PATENTS entitled to claim rights from [***] ([***]; [***]: [***]) of the patent family [***] of [***] that claim priority from French priority document [***] ([***]). PATENTS that include the aforesaid claims and that are granted as of the EFFECTIVE DATE are listed below:

[***]

3. PATENTS entitled to claim rights from [***] to [***], which application claims priority from [***]. PATENTS that are granted as of the EFFECTIVE DATE include [***]

 

24

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Exhibit 1.24 – REGISTERED AFFILIATES

 

25

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

EXHIBIT 1.25 – FORM OF MATERIAL TRANSFER AGREEMENT FOR STRATEGIC PARTNER

 

26

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

EXHIBIT 1.25 – FORM OF MATERIAL TRANSFER AGREEMENT FOR A CONTRACTOR

 

27

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Attachment I: Statement of Work to which the use of the MATERIAL is to be limited

Contractor may only use MATERIAL and INFORMATION for

 

28

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

EXHIBIT 2.4.2 – PRE-APPROVED THIRD PARTY CONTRACTORS

 

29

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Exhibit 3.5.1– Quarterly reporting form

To:

CRUCELL HOLLAND B.V.

Archimedesweg 4

P.O. Box 2048

2301 CA Leiden

THE NETHERLANDS

Attn. Business Development

FAX: +31-71-5248702

From: (Please fill in COMPANY name and address)

 

 

 

Date:                                         

Subject: QUARTERLY REPORT LICENSE AGREEMENT

 

  1) Period covered by the report

 

 

 

  2) General culturing

 

    A short description on general cell culture activities.

 

    Have you encountered problems culturing the PER.C6® cell line?

 

    Have you seen substantial deviations from the culture protocols described in the PER.C6® KNOW HOW FILE?

 

       
       
       
       
       
       
       
       
       
       
       

 

30

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  3) VECTOR production

 

    Number and types of Protein/MAB produced in the PER.C6® cell line.

 

    Have you encountered problems or observed remarkable results when transfecting the PER.C6® cell line, or when creating MODIFIED CELLS?

 

    Any substantial deviations from and/or additions to the protocols provided in the PER.C6® KNOW HOW FILE?

 

    Code(s) for tracking the individual Protein/MAB in future reports.

 

       
       
       
       
       
       
       
       
       
       
       

 

  4) Interactions with regulatory authorities

 

    In the past three months, were there any communications with regulatory authorities that were NOT subject to Section 3.4.3 of the License Agreement? If YES, please provide a summary of the reason, the nature and the outcome of these discussions. Please provide copies of the communication.

 

    What safety, tumorgenicity and/or other tests have been performed on the PACKAGING CELLS for regulatory purposes? Please provide reason, nature and outcome of the tests.

 

       
       
       
       
       
       
       
       
       
       
       

 

31

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

Exhibit 3.5.2. – Annual reporting form

To:

CRUCELL HOLLAND B.V.

Archimedesweg 4

P.O. Box 2048

2301 CA Leiden

THE NETHERLANDS

Attn. Business Development

FAX: +31-71-5248702

From: (Please fill in COMPANY name and address)

 

 

 

 

 

Date:                                                  

Subject: ANNUAL REPORT LICENSE AGREEMENT

 

  1) Period covered by the report
                

 

  2) General culturing

 

    A short description on general cell culture activities.

 

    Media used.

 

    Cell banks prepared.

 

    General performance; cell growth, viabilities, doubling times.

 

    Scale and scale-up data.

 

    Systems used (Shake-flasks, Roller bottles, Bioreactors, Wave bags).

 

    Have you encountered problems culturing the PER.C6® cell line?

 

    Have you seen substantial deviations from the culture protocols described in the PER.C6® KNOW HOW files?

 

       
       
       
       
       
       
       
       
       
       
       

 

32

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  3) VECTOR production

 

    Number and type of vectors produced in the PER.C6® cell line.

 

    Yields reached per produced VECTOR.

 

    Have you encountered problems or observed remarkable results when transfecting the PER.C6® cell line, or when creating MODIFIED CELLS?

 

    Any substantial deviations from and/or additions to the protocols provided in the PER.C6® KNOW HOW FILE?

 

    Code(s) for tracking the individual new PRODUCT in future reports.

 

       
       
       
       
       
       
       
       
       
       
       

 

  4) Third party activities

 

    Have you performed CMO activities for third parties using the PER.C6® cell line or worked with the PER.C6® cell line in collaborations programs with third parties? If yes, please state the name of the company/companies and a short description of the project(s).

 

    Has a CMO performed any activities with the PER.C6® cell line? If yes, please state the name of the company/companies and a short description of the project(s).

 

       
       
       
       
       
       
       
       
       
       
       

 

33

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Commercial License Agreement PER.C6®

Crucell Holland – Vascular Biogenics

 

  5) Interactions with regulatory authorities / Clinical activities

 

    What pre-IND meetings and IND filings have taken place for products produced on PER.C6®? For which products? What was the outcome (related to PER.C6®) of those meetings?

 

    Were there any communications with regulatory authorities that were NOT subject to Section 3.4.3 of the License Agreement? If YES, please provide a summary of the reason, the nature and the outcome of these discussions. Please provide copies of the communication.

 

    What safety, tumorgenicity and/or other tests have been performed on the PACKAGING CELLS for regulatory purposes. Please provide reason, nature and outcome of the tests.

 

    Was clinical material produced using the PER.C6® cell line?

 

       
       
       
       
       
       
       
       
       
       
       

 

34

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].

EX-10.4

Exhibit 10.4

AGREEMENT

This Agreement (“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between:

Tel Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Hashomer, Israel, 52621, represented by its authorized representatives (THM”); and

Prof. Dror Harats, ID no. 054496641 of Ramat Gan, Israel (“Prof. Harats”); and

Vascular Biogenics Ltd., Company no. 51-289976-6, a private company duly incorporated under the laws of the State of Israel having its registered office at 6 Yoni Netanyahu Street, Or Yehuda, Israel, 60376, represented by its authorized representatives (“VBL” or the “Company”).

 

WHEREAS: THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and

 

WHEREAS: THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees; and

 

WHEREAS: Prof. Harats has been an employee of the Hospital and/or the Fund since 1995; and

 

WHEREAS: VBL was established in 1999; and

 

WHEREAS: The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Prof. Harats, and certain other inventors defined herein as Inventors and VBL disagrees, denies and refutes all such claims in their entirety; and

 

WHEREAS: THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder;

NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties hereby agree and stipulate as follows:

 

1. PREAMBLE AND DEFINITIONS

 

  1.1 The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof.

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  1.2 The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement.

 

  1.3 In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter:

 

  1.3.1 Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only, “control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity.

 

  1.3.2 The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA).

 

  1.3.3 Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States, Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefore throughout the world; and (vi) all domain names, uniform resource locators, and other names and locators associated with the internet.

 

  1.3.4 The “Inventors” – As specifically detailed in Appendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba.

 

2

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  1.3.5 The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified in Appendix B attached hereto; (ii) any continuations in part of the Company’s IP listed in Appendix B; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in Appendix B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon.

 

  1.3.6 The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the Company’s IP.

 

  1.3.7 Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes, excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate uses; provided however that the Company doesn’t receive any consideration relating thereto;

 

     For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph (a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable.

 

  1.3.8 License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly.

 

  1.3.9

License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or after the First Commercial Sale in any country) by the Company in return for or in connection with the grant of Licences or the grant of an

 

3

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in respect of which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments, etc. but shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with detailed budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the ordinary course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause.

 

  1.3.10 First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such country has been obtained if such approval is required.

 

2. PARTIES’ DECLARATIONS AND UNDERTAKINGS

 

  2.1 THM undertakes and covenants as follows:

 

  2.1.1 Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right to receive any payment, compensation, funds or securities from Prof. Dror Harats and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights, claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s IP now or in the future, (“Released Matters”).

 

  2.1.2

Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and relates only to any part of the Company’s IP which is created, conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property

 

4

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or contractors on behalf of the Company to the extent they are not listed in Appendix A.

 

  2.1.3 Prof Harats shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and subject to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties.

 

  2.2 Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received.

 

3. LICENSE BY THE COMPANY

VBL undertakes that any License granted by it shall be subject to the following terms:

 

5

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  3.1 The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with such terms.

 

  3.2 The License is being granted in a bona fide arms-length commercial transaction.

 

  3.3 Non monetary consideration, if any, shall be valued as set forth in this Agreement.

 

4. CONSIDERATION TO THM

 

  4.1 VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country:

 

  4.1.1 Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”).

 

  4.1.2 Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the “Licensing Consideration”).

 

  4.2 The amounts payable to THM under clause 4.1 shall be paid as follows:

 

  4.2.1 Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL receives payment on account of Net Sales.

 

  4.2.2 Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL.

 

6

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  4.3 Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”).

Consideration from Exit Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may pay the Consideration From Exit within 12 months following the closing of the respective Exit Event.

Exit Event” means any of the following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile or structure of VBL shall not be deemed an Exit Event.

 

  4.4. Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM, provided that such amounts were not received by THM as Royalties under clause 4.1.1.

 

  4.5 All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount applicable to THM in connection with each payment.

 

  4.6 The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report the date of execution of such agreement and the date of the First Commercial Sale according to the agreement.

 

  4.7 In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be.

 

  4.8

The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in which any Net Sales are made, or License Fee received, in a form reasonably acceptable to THM, signed by the chief financial officer of VBL,

 

7

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made by the Company, Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity of Licensees, countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit Event specifying the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any agreement executed in connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts payable hereunder; and (c) Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM pursuant to this clause 4 in the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of such Exit will be disclosed orally by the legal counsel of VBL to the head of THM.

 

  4.9 The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices.

 

  4.10 Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of 4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year.

 

  4.11

Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following details, as updated from the last report: (i) the activities the

 

8

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  Company conducted for the development of Products; and (ii) sales and marketing efforts.

 

5. INDEMNITY

 

  5.1 VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a “THM Claim”).

 

  5.2     

 

  5.3 The following mechanism shall apply to any THM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of any THM Claim, such THM Beneficiary shall, as promptly as is reasonably possible, give VBL notice of such THM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the Beneficiary against such THM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of such THM Claim, that shall include the right to select and direct legal counsel and other consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion.

 

  5.4 VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product liability and (iii) commercial sales of applicable and relevant Products.

 

6. PATENT RIGHTS

In the event that the Company decides to abandon its patents in all applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM (“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights.

THM shall have the right to continue to support and maintain any such Patent Rights provided that it notifies VBL of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for the assignment or license of such Patent Rights to THM. The parties shall negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4

 

9

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


and that any such agreement shall be subject to any limitations and restrictions imposed by applicable third parties, including without limitation, the Office of the Chief Scientist and shall be subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period.

 

7. MISCELLANEOUS

 

  7.1 Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel.

 

  7.2 Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication including commercial publicity, without the prior written consent of THM.

 

  7.3 Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party. Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital. In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement.

 

  7.4

Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) upon personal delivery (ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid,

 

10

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  return receipt requested, if sent by Registered Mail and addressed to the address of the parties first above stated or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other method will be deemed to have been duly served upon receipt thereof.

 

  7.5 Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem expedient.

 

  7.6 Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties.

 

  7.7 Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations, or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings.

 

  7.8 THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work as medical doctors for Sheba such as Prof. Dror Charats, Prof. Shoenfeld and Prof. Gerge Jacob, shall belong to Sheba.

[Remainder of the Page was left intentionally blank]

 

11

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement.

 

Tel Hashomer - Medical Research,       Vascular Biogenics Ltd.
Infrastructure and Services Ltd.      
By:  

/s/ [Illegible]

      By:  

/s/ Dror Harats

/s/ Dror Harats

Prof. Dror Harats

       
Approved and Acknowledged        

/s/ [Illegible]

The Government of Israel

By the Ministry of Health

       

 

12

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Appendix A

INVENTORS

1. Prof. Dror Harats

2. Shoenfeld Yehuda

3. George Jacob

4. Halperin Gideon – up to 2003

5. Bloom Nira

6. Greenberger Shoshana

7. Tal Reshef

8. Peled Michael

 

* detailed list of inventions is provided under Appendix B.

 

13

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Appendix B’ up to 3 Feb 2013

 

METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS   

Our Ref

   Country      Earliest Priority    Entry Date    Filing Date
Application No.
     Issue Date
Patent No.
   SKGF Ref      Status      Inventor  

[***]

     [***]               [***]            [***]         [***]         [***]   

 

ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS    

Our Ref

   Country      Earliest Priority      Entry Date    Filing Date
Application No.
     Issue Date
Patent No.
   SKGF Ref      Status      Inventor  

[***]

     [***]               [***]               [***]         [***]   

52423

     PCT         19-Oct-2010            12/10/2011            3182.041PC01         Pending      

 

TREATMENT WITH VB-201   

Our Ref

   Country      Earliest Priority    Entry Date    Filing Date
Application No.
     Issue Date
Patent No.
   SKGF Ref    Status      Inventor  

[***]

     [***]               [***]               [***]         [***]   

 

14

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


[***]

   [***]   [***]      [***]        [***]   [***]

50378

   PCT   05-Jan-2010

61/292,226

     05-Jan-2011

IL2011/000012

  Publ. Date: 14-Jul-2011

Publ. #: WO2011/083469

  3182.018PC05    Expired   YACOV Niva; BREITBART
Eyal; MENDEL Itzhak; FEIGE
Erez; COHEN Yael

 

PAF-LIKE HOMOLOGS AND USES THEREOF

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status   Inventor

[***]

   [***]         [***]        [***]   [***]

44504

   PCT   16-Oct-2007

60/960,846

      05-Oct-2008

IL2008/001315

  Publ. Date: 23-Apr-2009

Publ. #: WO2009/050692

     Expired   YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

48215

   Israel

NP

  16-Oct-2007

60/960,846

   15-Apr-2010    05-Oct-2008

205144

    3182.019IL01    Aban   YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

48216

   USA

NP

  16-Oct-2007

60/960,846

   15-Apr-2010    05-Oct-2008

12/738,097

    3182.0190001    Aban   YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

48217

   Europe

NP

  16-Oct-2007

60/960,846

   14-May-2010    05-Oct-2008

08808113.8

    3182.019EP01    Aban   YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

 

15

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status   Inventor

[***]

   [***]         [***]        [***]   [***]
IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status   Inventor

28367

   PCT   09-Jul-2004

60/586,219

      10-Jul-2005

IL2005/000735

  Publ. Date: 19-Jan-2006

Publ. #: WO2006/006161

     Expired   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33799

   Israel

NP

  09-Jul-2004

60/586,219

   09-Jan-2007    10-Jul-2005   1-Mar-2012

180628

  3182.020IL00    GRANTED   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

50430

   Israel

DIV

  09-Jul-2004

60/586,219

   17-Mar-2011    10-Jul-2005

211795

       Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

50431

   Israel

DIV

  09-Jul-2004

60/586,219

   17-Mar-2011    10-Jul-2005

211796

       Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33793

   Europe

NP

  09-Jul-2004

60/586,219

   09-Feb-2007    10-Jul-2005

05758938.4

       Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33793 Div

   Europe

Div

  09-Jul-2004

60/586,219

   Oct 2012    10-Jul-2005     3182.020EP10    Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

 

16

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


33793 Div

   Europe

Div

  09-Jul-2004

60/586,219

  Oct 2012   10-Jul-2005

12179533.0

     3182.020EP20    Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

39643

   Hong Kong

NP

  09-Jul-2004

60/586,219

  31-May-2007   10-Jul-2005

07105789.7

        Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33795

   Canada

NP

  09-Jul-2004

60/586,219

  09-Jan-2007   10-Jul-2005

2,573,396

        Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33796

   Japan

NP

  09-Jul-2004

60/586,219

  09-Jan-2007   10-Jul-2005

2007-519983

  24-Jun-2011

4,767,948

      Granted   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

48896

   Japan

DIV

  09-Jul-2004

60/586,219

  21-May-2010   10-Jul-2005

2010-116964

        Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33797

   Republic of Korea

NP

  09-Jul-2004

60/586,219

  09-Feb-2007   10-Jul-2005

2007-7003288

  9-Nov-2012

10-1201935

      Granted   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33798

   China

NP

  09-Jul-2004

60/586,219

  28-Feb-2007   10-Jul-2005

200580029218.9

  3-Aug-2011

200580029218.9

      Granted   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

48018

   China

DIV

  09-Jul-2004

60/586,219

  11-Feb-2010   10-Jul-2005

201010128184.1

        Pending   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

[***]

   [***]   [***]   [***]   [***]         [***]   [***]

33801

   Russian Federation

NP

  09-Jul-2004

60/586,219

  09-Feb-2007   10-Jul-2005

2007105097

  20-Sep-2010

2399626

      Granted   HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

 

17

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


33802

   Mexico

NP

   09-Jul-2004

60/586,219

   08-Jan-2007    10-Jul-2005

MX/a/
2007/000361

   17-Mar-2011

284830

      Granted    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33803

   Australia

DIV

   09-Jul-2004

60/586,219

   09-Jan-2007    10-Jul-2005

2007200090

   2007200090

5 Jan 2012

   3182.020AU00    Granted    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

50536

   Mexico

DIV

   09-Jul-2004

60/586,219

   14-Jan-2011    10-Jul-2005

MX/a/
2011/000630

   3 Sep 2012

303011

      Granetd    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33804

   New Zealand

NP

   09-Jul-2004

60/586,219

   09-Feb-2007    10-Jul-2005

553147

   06-Nov-2010

553147

      Granted    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

48999

   New Zealand

DIV

   09-Jul-2004

60/586,219

   29-Jun-2010    10-Jul-2005

586503

   10 Oct 2011

586503

      Granted    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

33805

   South Africa

NP

   09-Jul-2004

60/586,219

      10-Jul-2005

2007/01178

   25-Sep-2008

2007/01178

      Granted    HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

 

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME

Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.
   Issue Date
Patent No.
  

SKGF Ref

   Status    Inventor

02/23345

   USA

CIP

   17-Nov-2000

60/248,582

      01-May-2002

10/135,447

   27-Jun-2006

7,067,649

      Granted    HARATS Dror; BREITBART
Eyal; BLOOM Nira

28786

   USA

DIV

   17-Nov-2000

60/248,582

   29-Oct-2004    01-May-2002

10/975,619

   25-Aug-2009

7,579,327

      Granted    HARATS Dror; BREITBART
Eyal; BLOOM Nira

 

18

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


45023

   USA

DIV

  17-Nov-2000

60/248,582

  03-Jun-2009   01-May-2002

12/457,200

         Pending       HARATS Dror; BREITBART

Eyal; BLOOM Nira

50926

   USA

DIV

  17-Nov-2000

60/248,582

  27-Apr-2011   01-May-2002

13/094,900

         Pending       HARATS Dror; BREITBART

Eyal; BLOOM Nira

53777

   USA

DIV

  17-Nov-2000

60/248,582

  24-April 2012   01-May-2002

13/454,171

    3182.0350004      Pending       HARATS Dror; BREITBART

Eyal; BLOOM Nira

25974

   PCT   01-May-2002

10/135,447

    30-Apr-2003

IL03/00347

  Publ. Date: 13-
Nov-2003

Publ. #: WO03/093409

       Expired       HARATS Dror

28650

   Singapore

NP

  01-May-2002

10/135,447

  01-Nov-2004   30-Apr-2003

200406381-4

  30-May-2008

107841 [WO 03/093409]

       Granted       HARATS Dror; BREITBART

Eyal; BLOOM Nira

28655

   South Africa

NP

  01-May-2002

10/135,447

  05-Nov-2004   30-Apr-2003

2004/8989

  26-Jul-2006

2004/8989

       Granted       HARATS Dror; BREITBART

Eyal; BLOOM Nira

[***]

   [***]   [***]   [***]   [***]   [***]        [***]       [***]

28646

   Japan

NP

  01-May-2002

10/135,447

  01-Nov-2004   30-Apr-2003

2004-501545

         Abandoned       HARATS Dror

[***]

   [***]   [***]   [***]   [***]   [***]        [***]       [***]

 

19

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


[***]

   [***]   [***]   [***]   [***]         [***]   [***]

28651

   Canada

NP

  01-May-2002

10/135,447

  01-Nov-2004   30-Apr-2003

2,483,996

        Abandoned   HARATS Dror; BREITBART
Eyal; BLOOM Nira

28652

   Mexico

NP

  01-May-2002

10/135,447

  28-Oct-2004   30-Apr-2003

PA/a/2004/010711

        Abandoned   HARATS Dror; BREITBART
Eyal; BLOOM Nira

[***]

   [***]   [***]   [***]   [***]         [***]   [***]

 

COMBINED TREATMENT UTILIZING VB-201

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status   Inventor

[***]

   [***]         [***]        [***]   [***]

50379

   PCT   05-Jan-2010

61/292,226

      05-Jan-2011

IL2011/000010

  Publ. Date: 14-Jul-2011

Publ. #: WO2011/083467

     Expired   YACOV Niva; BREITBART
Eyal; COHEN Yael
   US NP   05-Jan-2010

61/292,226

   5-July 2012    05-Jan-2011

13/520,713

    3182.0160005    Pending   YACOV Niva; BREITBART
Eyal; COHEN Yael
   EP NP   05-Jan-2010

61/292,226

   1-Aug 2012        3182.016EP05    Pending   YACOV Niva; BREITBART
Eyal; COHEN Yael

 

20

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


   JP NP    05-Jan-2010

61/292,226

   4-July 2012          3182.016JP05    Pending    YACOV Niva; BREITBART
Eyal; COHEN Yael

 

POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status   Inventor

[***]

   [***]         [***]        [***]   [***]

41795

   PCT   31-Jul-2006

60/834,157

      31-Jul-2007

IL2007/000959

  Publ. Date: 07-Feb-2008

Publ. #: WO/2008/015675

     Expired   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45501

   China

NP

  31-Jul-2006

60/834,157

   26-Mar-2009    31-Jul-2007

200780035863.0

  8-Aug 2012

ZL20078003 5863.0

  3182.040CN01    Granted   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

54283

   China

Div

  31-Jul-2006

60/834,157

   26-June-2012    31-Jul-2007

201210210646.3

    3182.040CN11    Pending   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45495

   USA

NP

  31-Jul-2006

60/834,157

   02-Feb-2009    31-Jul-2007

12/309,856

       Abandoned   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

51521

   USA

DIV

  31-Jul-2006

60/834,157

   20-Jun-2011    31-Jul-2007

13/163,776

       Pending   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45496

   Israel

NP

  31-Jul-2006

60/834,157

   29-Jan-2009    31-Jul-2007

196792

       Pending   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

 

21

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


[***]

   [***]   [***]   [***]   [***]         [***]   [***]

45499

   Australia

NP

  31-Jul-2006

60/834,157

  02-Feb-2009   31-Jul-2007

2007280017

  26-July 2012

2007280017

   3182.040AU01    Granted   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

54370

   Australia

Div

  31-Jul-2006

60/834,157

  12-July 2012   31-Jul-2007

2012204128

     3182.040AU11    Pending   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45500

   Japan

NP

  31-Jul-2006

60/834,157

  02-Feb-2009   31-Jul-2007

2009-522416

        Pending   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45502

   Republic of Korea

NP

  31-Jul-2006

60/834,157

  27-Feb-2009   31-Jul-2007

2009-7004288

        Abandoned   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45503

   Mexico

NP

  31-Jul-2006

60/834,157

  29-Jan-2009   31-Jul-2007

MX/a/
2009/001157

        Pending   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

45504

   New Zealand

NP

  31-Jul-2006

60/834,157

  26-Jan-2009   31-Jul-2007

574410

  9 July 2012

574410

   3182.040NZ01    Granted   TAL Reshef; BREITBART
Eyal; BANGIO Livnat

 

22

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


45505

   South Africa

NP

   31-Jul-2006

60/834,157

   26-Jan-2009    31-Jul-2007

2009/00581

   31-Mar-2010

2009/00581

     Granted   

TAL Reshef; BREITBART

Eyal; BANGIO Livnat

45506

   Singapore

NP

   31-Jul-2006

60/834,157

   30-Jan-2009    31-Jul-2007

200900642-0

   30-Jun-2011

149616[WO2008/015675]

     Granted   

TAL Reshef; BREITBART

Eyal; BANGIO Livnat

 

TREATMENT WITH VB-201

Our Ref

   Country   Earliest Priority   Entry Date   Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref   Status   Inventor

[***]

   [***]   [***]     [***]       [***]   [***]

50377

   PCT   05-Jan-2010

61/292,226

    05-Jan-2011

IL2011/000008

  Publ. Date: 14-Jul-2011

Publ. #: WO2011/083465

    Expired   YACOV Niva; BREITBART
Eyal; MENDEL Itzhak;
SHER Naamit; COHEN Yael
   US NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011     3182.0170005   Pending  
   AU NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011     3182.017AU05   Pending  
   [***]   [***]   [***]   [***]     [***]   [***]  
   CANADA NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011     3182.017CA05   Pending  

 

23

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


   China NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011      3182.017CN05   Pending  
   HK NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011      3182.017HK05   Pending  
   EP NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011      3182.017EP05   Pending  
   [***]   [***]   [***]   [***]      [***]   [***]  
   Japan NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011      3182.017JP05   Pending  
   South Korea NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011      3182.017KR05   Pending  
   MX NP   05-Jan-2010

61/292,226

  June 2012   05-Jan-2011      3182.017MX05   Pending  
   [***]   [***]   [***]   [***]      [***]   [***]  

 

24

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF

Our Ref

   Country   Earliest Priority   Entry Date   Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref   Status   Inventor

[***]

   [***]       [***]       [***]   [***]
METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL PREPARATIONS GENERATED THEREBY

Our Ref

   Country   Earliest Priority   Entry Date   Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref   Status   Inventor

49684

   PCT   12-Jan-2010

61/294,158

    12-Jan-2011

IB2011/050137

  Publ. Date: 21-Jul-2011

Publ. #: WO2011/086509

    Expired   BREITBART Eyal; BANGIO
Livnat; SHER Naamit
   US NP   12-Jan-2010

61/294,158

  June 2012   12-Jan-2011     3182.0330001   Pending   BREITBART Eyal; BANGIO
Livnat; SHER Naamit
   EP NP   12-Jan-2010

61/294,158

  June 2012   12-Jan-2011     3182.033EP01   Pending   BREITBART Eyal; BANGIO
Livnat; SHER Naamit
   [***]   [***]   [***]   [***]     [***]   [***]   [***]
   JP NP   12-Jan-2010

61/294,158

  June 2012   12-Jan-2011     3182.033JP01   Pending   BREITBART Eyal; BANGIO
Livnat; SHER Naamit
   [***]   [***]   [***]   [***]     [***]   [***]   [***]

 

25

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status  

Inventor

[***]

   [***]         [***]        [***]   [***]
METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status  

Inventor

01/22753

   PCT   24-Nov-2000

60/252,574

      22-Nov-2001

IL01/01080

  Publ. Date: 30-May-2002

Publ. #: WO02/41827

     Expired   HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26035

   Europe

NP

  22-Nov-2000

60/252,574

   15-May-2003    22-Nov-2001

01997274.4

       Pending   HARATS Dror; GEORGE Jacob; HALPERIN Gideon

52529

   EP Div   22-Nov-2000

60/252,574

   17-Nov 2011    22-Nov-2001

11189562.9

    3182.021EP11    Pending   HARATS Dror; GEORGE Jacob; HALPERIN Gideon

27265

   Hong Kong

NP

  24-Nov-2000

60/252,574

   12-Dec-2003    22-Nov-2001

03109096.1

       Pending   HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26036

   Israel

NP

  22-Nov-2000

60/252,574

   20-May-2003    22-Nov-2001

156015

  10-May-2008

156015

     Granted   HARATS Dror; GEORGE Jacob; HALPERIN Gideon

32434

   Israel

DIV

  24-Nov-2000

60/252,574

   20-Jul-2006    22-Nov-2001

176976

  1-Dec 2012

176976

  3182.021IL11    Granted   HARATS Dror; GEORGE Jacob; HALPERIN Gideon

 

26

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


26037

   India

NP

   22-Nov-2000

60/252,574

   22-May-2003    22-Nov-2001

796/CHENP/2003

   19-Sep-2008

223638

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26039

   Canada

NP

   22-Nov-2000

60/252,574

   22-May-2003    22-Nov-2001

2,429,817

      3182.021CA01    Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26040

   Australia

NP

   22-Nov-2000

60/252,574

   23-May-2003    22-Nov-2001

2002218461

   21-Dec-2006

2002218461

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26041

   Japan

NP

   22-Nov-2000

60/252,574

   23-May-2003    22-Nov-2001

2002-544008

   01-Aug-2008

4,162,486

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

44299

   Japan

DIV

   24-Nov-2000

60/252,574

   10-Jun-2008    22-Nov-2001

2008-151301

   25 May 2012

5001906

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26042

   China

NP

   22-Nov-2000

60/252,574

   22-Jul-2003    22-Nov-2001

01822215.3

   06-Jan-2010

ZL01822215.3

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26043

   Republic of Korea

NP

   22-Nov-2000

60/252,574

   24-May-2003    22-Nov-2001

2003-7006991

   17-Oct-2008

865142

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

26044

   Mexico

NP

   22-Nov-2000

60/252,574

   22-May-2003    22-Nov-2001

PA/a/2003/004517

   02-Sep-2009

269738

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

46494

   Mexico

DIV

   24-Nov-2000

60/252,574

   12-Jun-2009    22-Nov-2001

MX/a/2009/006365

   2 December 2011

293020

   3182.021MX11    Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

 

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

27

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.
   Issue Date
Patent No.
  SKGF Ref    Status   

Inventor

36194

   USA

CIP

   17-Nov-2000

60/248,582

      30-Apr-2007

11/790,992

        Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

43177

   PCT    30-Apr-2007

11/790,992

      27-Apr-2008

IL2008/000543

   Publ. Date: 06-Nov-2008

Publ. #: WO2008/132729

     Expired    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47030

   Europe

NP

   30-Apr-2007

11/790,992

   27-Nov-2009    27-Apr-2008

08738245.3

        Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

48882

   Hong Kong

NP

   30-Apr-2007

11/790,992

   11-Jun-2010    27-Apr-2008

10105838.3

        Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47031

   Japan

NP

   30-Apr-2007

11/790,992

   30-Oct-2009    27-Apr-2008

2010-505002

        Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47032

   Canada

NP

   30-Apr-2007

11/790,992

   27-Oct-2009    27-Apr-2008

2,685,394

        Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47033

   China

NP

   30-Apr-2007

11/790,992

   30-Dec-2009    27-Apr-2008

200880022935.2

     3182.039CN01    Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

 

28

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


47034

  

Australia

NP

   30-Apr-2007

11/790,992

  27-Nov-2009   27-Apr-2008

2008243817

        Pending   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47035

  

Republic of Korea

NP

   30-Apr-2007

11/790,992

  18-Nov-2009   27-Apr-2008

2009-7024041

        Pending   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

[***]

   [***]    [***]   [***]   [***]         [***]   [***]

47037

  

Israel

NP

   30-Apr-2007

11/790,992

  26-Oct-2009   27-Apr-2008

201760

        Pending   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47038

  

Mexico

NP

   30-Apr-2007

11/790,992

  29-Oct-2009   27-Apr-2008

MX/a/2009/011750

        Pending   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47039

  

New Zealand

NP

   30-Apr-2007

11/790,992

  27-Nov-2009   27-Apr-2008

581511

  5 June 2012

581511

   3182.039NZ01    Granetd   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47040

  

South Africa

NP

   30-Apr-2007

11/790,992

  25-Nov-2009   27-Apr-2008

2009/08331

  29-Dec-2010

2009/08331

      Granted   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47041

  

Singapore

NP

   30-Apr-2007

11/790,992

  30-Oct-2009   27-Apr-2008

200907209-1

  15 May 2012

156740

   3182.039SG01    Granted   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

 

29

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR DEFICIENT MICE

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status  

Inventor

[***]

   [***]         [***]        [***]   [***]
METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

Our Ref

   Country   Earliest Priority    Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
  SKGF Ref    Status  

Inventor

01/23033

   PCT   04-Jan-2001

60/259,512

      03-Jan-2002

IL02/00005

  Publ. Date: 11-Jul-2002

Publ. #: WO02/053092

     Expired   HARATS Dror; GEORGE Jacob

26046

   Israel

NP

  04-Jan-2001

60/259,512

   03-Jul-2003    03-Jan-2002

156770

       Allowed   HARATS Dror; GEORGE Jacob

26047

   India

NP

  04-Jan-2001

60/259,512

   04-Jul-2003    03-Jan-2002

1044/CHENP/
2003

  19-Sep-2008

223640

     Granted   HARATS Dror; GEORGE Jacob

26048

   USA

NP

  04-Jan-2001

60/259,512

   02-Jul-2003    03-Jan-2002

10/451,370

  09-Oct-2007

7,279,459

     Granted   HARATS Dror; GEORGE Jacob

26050

   Australia

NP

  04-Jan-2001

60/259,512

   11-Jul-2003    03-Jan-2002

2002225301

  03-Mar-2006

2002225301

     Granted   HARATS Dror; GEORGE Jacob

 

30

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


26051

   Japan

NP

  04-Jan-2001

60/259,512

  03-Jul-2003   03-Jan-2002

2002-554043

  26-Sep-2008

4,191,997

      Granted   HARATS Dror; GEORGE Jacob

26052

   China

NP

  04-Jan-2001

60/259,512

  04-Sep-2003   03-Jan-2002

02805950.6

        Pending   HARATS Dror; GEORGE Jacob

26054

   Mexico

NP

  04-Jan-2001

60/259,512

  01-Jun-2003   03-Jan-2002

PA/a/2003/006043

  17-Mar-2009

265173

      Granted   HARATS Dror; GEORGE Jacob

26045

   Europe

NP

  04-Jan-2001

60/259,512

  18-Jul-2003   03-Jan-2002

02715682.7

        Abandoned   HARATS Dror; GEORGE Jacob

27463

   Hong Kong

NP

  04-Jan-2001

60/259,512

  28-Jan-2004   03-Jan-2002

04100565.1

        Abandoned   HARATS Dror; GEORGE Jacob

26049

   Canada

NP

  04-Jan-2001

60/259,512

  03-Jul-2003   03-Jan-2002

2,433,781

        Abandoned   HARATS Dror; GEORGE Jacob

[***]

   [***]   [***]   [***]   [***]         [***]   [***]
FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS

Our Ref

   Country   Earliest Priority   Entry Date   Filing Date
Application No.
  Issue Date
Patent No.
   SKGF Ref    Status  

Inventor

[***]

   [***]       [***]         [***]   [***]

 

31

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


   PCT    Sept. 1, 2011

61/529,989

      Aug. 31, 2012

PCT/US2012/053533

     3182.013PC01    Pending    SHER Naamit; YOUNG Victor M.; McNAUGHTON Alyn; WILDING Ian; BAKHSHAEE Massoud
PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.
   Issue Date
Patent No.
 

 

   Status   

Inventor

31577

   USA

CIP

   17-Nov-2000

60/248,582

      23-Feb-2006

11/359,513

   18 October 2011

8,039,261

  3182.0380000    Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

37180

   PCT    23-Feb-2006

11/359,513

      22-Feb-2007

IL2007/000242

   Publ. Date: 30-Aug-2007

Publ. #: WO2007/096882

     Expired    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

44720

   USA

NP

   17-Nov-2000

60/248,582

   20-Aug-2008    22-Feb-2007

12/224,178

        Abandoned    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

44708

   Europe

NP

   23-Feb-2006

11/359,513

   28-Aug-2008    22-Feb-2007

07713267.8

        Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

 

32

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


[***]

   [***]   [***]   [***]   [***]         [***]   [***]

44709

   Israel

NP

  23-Feb-2006

11/359,513

  19-Aug-2008   22-Feb-2007

193554

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

[***]

   [***]   [***]   [***]   [***]         [***]   [***]

44711

   Canada

NP

  23-Feb-2006

11/359,513

  20-Aug-2008   22-Feb-2007

2,638,829

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

44712

   Australia

NP

  23-Feb-2006

11/359,513

  23-Sep-2008   22-Feb-2007

2007219088

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

44713

   Japan

NP

  23-Feb-2006

11/359,513

  25-Aug-2008   22-Feb-2007

2008-555946

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

44714

   China

NP

  23-Feb-2006

11/359,513

  21-Oct-2008   22-Feb-2007

200780014285.2

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

44715

   Republic of Korea

NP

  23-Feb-2006

11/359,513

  22-Sep-2008   22-Feb-2007

2008-7023144

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

44716

   Mexico

NP

  23-Feb-2006

11/359,513

  22-Aug-2008   22-Feb-2007

MX/a/2008/010859

        Abandoned   HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; PELED Michael; BANGIO Livnat

[***]

   [***]   [***]   [***]   [***]         [***]   [***]

 

33

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.
  

Issue Date

Patent No.

  

SKGF Ref

   Status   

Inventor

33794

   USA

CIP

   09-Jul-2004

60/586,219

      09-Jan-2007

11/650,973

  

05-Oct-2010

7,807,847

   3182.0200001    Granted    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

49396

   USA

DIV

   09-Jul-2004

60/586,219

   24-Aug-2010    09-Jan-2007

12/861,921

  

28- Feb 2012

8,124,800

   3182.0200002    Granted    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

52800

   USA DIV    09-Jul-2004

60/586,219

   May 24, 2012    January 26, 2012

13/358,573

      3182.0200003    Pending    HALPERIN Gideon; KOVALEVSKI
   USA CIP    09-Jul-2004

60/586,219

      Nov. 9, 2012

13/672,811

      3182.0200004    Pending    HALPERIN Gideon; KOVALEVSKI
   US CON    09-Jul-2004

60/586,219

      Dec. 10, 2012

13/709,198

      3182.0200005    Pending    HALPERIN Gideon; KOVALEVSKI

 

IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

34

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

43029

   PCT   

09-Jan-2007

11/650,973

     

02-Jan-2008

IL2008/000013

  

Publ. Date: 17-Jul-2008

Publ. #: WO2008/084472

      Expired    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46756

  

South Africa

NP

  

09-Jan-2007

11/650,973

     

02-Jan-2008

2009/05601

  

26-May-2010

2009/05601

      Granted    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46755

  

New Zealand

NP

  

09-Jan-2007

11/650,973

   07-Aug-2009   

02-Jan-2008

578947

  

4-Dec 2011

578947

   3182.020NZ01    Granted    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

51026

  

New Zealand

DIV

  

09-Jan-2007

11/650,973

   15-Jun-2011   

02-Jan-2008

593529

      3182.020NZ11    Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
   [***]    [***]    [***]    [***]       [***]    [***]    [***]

46754

  

Australia

NP

  

09-Jan-2007

11/650,973

   07-Aug-2009   

02-Jan-2008

2008204238

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46753

  

Mexico

NP

  

09-Jan-2007

11/650,973

   09-Jul-2009   

02-Jan-2008

MX/a/2009/007422

  

9-Jan 2012

294470

      Granted    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
   [***]    [***]    [***]    [***]          [***]    [***]

46751

  

Israel

NP

  

09-Jan-2007

11/650,973

   09-Jul-2009   

02-Jan-2008

199792

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46750

  

China

NP

  

09-Jan-2007

11/650,973

   31-Aug-2009   

02-Jan-2008

200880006707.6

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

 

35

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


46749

  

Republic of Korea

NP

  

09-Jan-2007

11/650,973

   27-Jul-2009   

02-Jan-2008

2009-7015780

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46748

  

Japan

NP

  

09-Jan-2007

11/650,973

   09-Jul-2009   

02-Jan-2008

2009-545295

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46747

  

Canada

NP

  

09-Jan-2007

11/650,973

   06-Jul-2009   

02-Jan-2008

2,674,902

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

46746

  

Europe

NP

  

09-Jan-2007

11/650,973

   07-Aug-2009   

02-Jan-2008

08700247.3

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
  

Europe

Div

  

09-Jan-2007

11/650,973

   July 27, 2012   

02-Jan-2008

EP 12178298.1

      3182.020EP11    Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti

48328

  

Hong Kong

NP

      16-Mar-2010   

02-Jan-2008

10102729.2

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti
COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]          [***]          [***]    [***]
METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT

 

36

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]    [***]       [***]          [***]    [***]

50375

   PCT   

05-Jan-2010

61/282,228

     

05-Jan-2011

IL2011/000007

  

Publ. Date: 14-Jul-2011

Publ. #: WO2011/083464

      Expired    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
   US NP   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.0310002    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
   EP   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.031EP02    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
   IL   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.031IL02    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
   [***]       [***]    [***]       [***]    [***]    [***]
   JP   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.031JP02    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
   [***]       [***]    [***]       [***]    [***]    [***]
   MX   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.031MX02    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael

 

37

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


   [***]    [***]    [***]    [***]       [***]    [***]    [***]
  

Canada

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.031CA02    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
  

Au

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.031AU02    Pending    BREITBART Eyal; BANGIO Livnat; SHER Naamit; FEIGE Erez; COHEN Yael
COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]    [***]       [***]          [***]    [***]

50376

   PCT   

05-Jan-2010

61/282,228

     

05-Jan-2011

IL2011/000009

  

Publ. Date: 14-Jul-2011

Publ. #: WO2011/083466

   3182.032PC02    Expired    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.

 

38

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


  

US NP

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.0320002    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
  

EU NP

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032EP02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
  

IL NP

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032IL02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
  

[***]

  

[***]

  

[***]

  

[***]

     

[***]

  

[***]

  

[***]

  

JP NP

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032JP02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
  

KR NP

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032KR02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
  

MX NP

  

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032MX02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
  

[***]

  

[***]

  

[***]

  

[***]

     

[***]

  

[***]

  

[***]

 

39

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


   CA NP   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032CA02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
   AU NP   

05-Jan-2010

61/282,228

   June 2012    05-Jan-2011       3182.032AU02    Pending    BREITBART Eyal; BANGIO Livnat; COHEN Yael; BRENNER Andrew J.
OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

Our Ref

  

Country

  

Earliest Priority

  

Entry
Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

       

Status

  

Inventor

32516

  

USA

CIP

  

27-May-2003

10/445,347

     

28-Sep-2006

11/528,657

  

01-Dec-2009

7,625,882

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; MENDEL Itzhak

46643

  

USA

DIV

  

27-May-2003

10/445,347

   14-Oct-2009   

28-Sep-2006

12/588,371

  

05-Jul-2011

7,973,023

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; MENDEL Itzhak

50968

  

USA

CON

  

27-May-2003

10/445,347

   13-Apr-2011   

28-Sep-2006

13/085,542

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; MENDEL Itzhak

 

AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF ATHEROSCLEROSIS

 

40

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.
   Issue Date
Patent No.
  SKGF Ref    Status   

Inventor

00/21414

   Israel

Basic

         04-Oct-1998

126447

   30-Dec-2004

126447

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS

Our Ref

   Country    Earliest Priority    Entry Date    Filing Date
Application No.
   Issue Date
Patent No.
  SKGF Ref    Status   

Inventor

01/21558

   PCT    04-Oct-1998

126447

   01-Apr-2001    30-Sep-1999

IL99/00519

   Publ. Date: 13-Apr-2000

Publ. #: WO00/20019

     Expired    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21884

   Europe

NP

   04-Oct-1998

126447

      30-Sep-1999

99970026.3

   14-May-2003

1126867

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21886

   Canada

NP

   04-Oct-1998

126447

      30-Sep-1999

2,345,445

   24-Aug-2010

2,345,445

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21887

   Australia

NP

   04-Oct-1998

126447

      30-Sep-1999

59966/99

   28-Aug-2003

760582

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21888

   China

NP

   04-Oct-1998

126447

   04-Apr-2001    30-Sep-1999

99814030.9

   24-Nov-2004

ZL99814030.9

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

02/23904

   Hong Kong

NP

   04-Oct-1998

126447

   19-Jul-2002    30-Sep-1999

02105365.4

   18-Nov-2005

HK1043743

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

28590

   China

DIV

   04-Oct-1998

126447

   23-Sep-2004    30-Sep-1999

200410011940.7

   05-Nov-2008

ZL200410011940.7

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

30562

   Hong Kong

DIV

   04-Oct-1998

126447

   28-Sep-2005    30-Sep-1999

05108561.7

   21-Aug-2009

HK1076600

     Granted    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

 

41

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


01/21889

   Singapore

NP

  04-Oct-1998

126447

     30-Sep-1999

200101998-3

  30-Apr-2003

80182

      Granted   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21890

   Japan

NP

  04-Oct-1998

126447

     30-Sep-1999

2000-573378

        Pending   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21891

   Hungary

NP

  04-Oct-1998

126447

  30-Sep-1999    30-Sep-1999

P0104410

        Pending   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

[***]

   [***]   [***]      [***]         [***]   [***]

01/21893

   Republic of Korea

NP

  04-Oct-1998

126447

     30-Sep-1999

2001-7004285

  02-Feb-2007

680707

      Granted   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/21885

   USA

NP

  04-Oct-1998

126447

  30-Mar-2001    30-Sep-1999

09/806,400

        Abandoned   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob

01/22498

   USA

CON

  04-Oct-1998

126447

  04-Sep-2001    30-Sep-1999

09/944,592

        Abandoned   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE

Our Ref

   Country   Earliest Priority   Entry Date    Filing Date
Application No.
  Issue Date
Patent No.
   SKGF Ref    Status  

Inventor

28919

   USA

CIP

  04-Oct-1998

126447

     15-Apr-2005

11/106,665

        Abandoned   HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

 

42

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

26038

  

USA

CIP

  

22-Nov-2000

60/252,574

     

27-May-2003

10/445,347

  

04-Jan-2005

6,838,452

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

27041

  

USA

DIV

  

24-Nov-2000

60/252,574

   24-Nov-2003   

27-May-2003

10/718,596

  

06-Mar-2007

7,186,704

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

29890

  

USA

DIV

  

24-Nov-2000

60/252,574

   19-Jul-2005   

27-May-2003

11/183,884

  

17-Mar-2009

7,504,388

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

45347

  

USA

DIV

  

24-Nov-2000

60/252,574

   17-Feb-2009   

27-May-2003

12/371,930

  

22-Feb-2011

7,893,291

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

50439

  

USA

CON

  

24-Nov-2000

60/252,574

   06-Jan-2011   

27-May-2003

12/985,365

  

17 April 2012

8,158,611

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

53355

  

USA

CON

  

24-Nov-2000

60/252,574

   March 27, 2012   

27-May-2003

13/431,262

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

 

43

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

27909

   PCT   

27-May-2003

10/445,347

     

27-May-2004

IL2004/000453

  

Publ. Date: 09-Dec-2004

Publ. #: WO2004/106486

      Expired    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

31532

  

USA

NP

  

27-May-2003

10/445,347

   25-Apr-2008   

27-May-2004

10/567,543

  

08-Mar-2011

7,902,176

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30958

  

Mexico

NP

  

27-May-2003

10/445,347

   25-Nov-2005   

27-May-2004

pa/A/2005/012784

  

14-Oct-2008

261341

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

30947

  

Europe

NP

  

27-May-2003

10/445,347

   07-Dec-2005   

27-May-2004

04735088.9

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

32340

  

Hong Kong

NP

  

27-May-2003

10/445,347

   03-Aug-2006   

27-May-2004

06108608.1

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30948

  

Japan

NP

  

27-May-2003

10/445,347

   30-Nov-2005   

27-May-2004

2006-531006

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva
   [***]    [***]    [***]    [***]       [***]    [***]    [***]

 

44

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


30949

  

Canada

NP

  

27-May-2003

10/445,347

   28-Nov-2005   

27-May-2004

2,527,483

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30950

  

China

NP

  

27-May-2003

10/445,347

   01-Nov-2005   

27-May-2004

200480021217.5

  

22-Dec-2010

ZL200480021217.5

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

49865

  

China

DIV

  

27-May-2003

10/445,347

   25-Oct-2010   

27-May-2004

201010537971.1

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30951

  

Australia

NP

  

27-May-2003

10/445,347

   13-Dec-2005   

27-May-2004

2004243695

  

17-Mar-2011

2004243695

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30952

  

Republic of Korea

NP

  

27-May-2003

10/445,347

   28-Nov-2005   

27-May-2004

2005-7022741

  

3-Nov 2011

1081977

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

50809

  

Republic of Korea

DIV

  

27-May-2003

10/445,347

   18-Feb-2011   

27-May-2004

2011-7003840

  

23 Feb 2012

10-1122160

      Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30953

  

New Zealand

NP

  

27-May-2003

10/445,347

   01-Dec-2005   

27-May-2004

544285

  

12-Mar-2009

544285

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

 

45

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


30954

  

South Africa

NP

  

27-May-2003

10/445,347

   01-Dec-2005   

27-May-2004

2005/09929

  

27-Dec-2006

2005/9929

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

30955

  

India

NP

  

27-May-2003

10/445,347

   27-Dec-2005   

27-May-2004

3555/CHENP/2005

  

26-Mar-2009

232654

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

30957

  

Russian Federation

NP

  

27-May-2003

10/445,347

   01-Dec-2005   

27-May-2004

2005140666

  

27-Jul-2009

2362567

      Granted    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

46052

  

Russian Federation

DIV

  

27-May-2003

10/445,347

   06-Apr-2009   

27-May-2004

2009112686

         Pending    HARATS Dror; GEORGE Jacob; HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva

 

OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]    [***]          [***]          [***]    [***]

 

46

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


46530

   PCT   

08-Oct-2008

61/103,571

     

01-Oct-2009

IL2009/000949

  

Publ. Date: 15-Apr-2010

Publ. #: WO2010/041242

      Expired    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50053

  

USA

NP

  

08-Oct-2008

61/103,571

   06-Apr-2011   

01-Oct-2009

13/122,766

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50054

  

Europe

NP

  

08-Oct-2008

61/103,571

   20-Apr-2011   

01-Oct-2009

09818874.1

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50055

  

Israel

NP

  

08-Oct-2008

61/103,571

   05-Apr-2011   

01-Oct-2009

212153

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

 

COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]          [***]          [***]    [***]

 

47

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


31865

   PCT   

15-Apr-2005

60/671,500

     

11-Apr-2006

IL2006/000467

  

Publ. Date: 19-Oct-2006

Publ. #: WO2006/109312

      Expired    YACOV Niva; BREITBART Eyal

41853

  

Europe

NP

  

15-Apr-2005

60/671,500

   24-Oct-2007   

11-Apr-2006

06728268.1

         Abandoned    YACOV Niva; BREITBART Eyal

41854

  

USA

NP

  

15-Apr-2005

60/671,500

   10-Oct-2007   

11-Apr-2006

11/918,141

         Abandoned    YACOV Niva; BREITBART Eyal

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

 

NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]          [***]          [***]    [***]
OXIDIZED LIPID COMPOUNDS AND USES THEREOF

 

48

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

45018

   PCT   

06-Nov-2008

61/193,220

     

05-Nov-2009

IL2009/001049

  

Publ. Date: 14-May-2010

Publ. #: WO2010/052718

      Expired   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50603

  

USA

NP

  

06-Nov-2008

61/193,220

   05-May-2011   

05-Nov-2009

13/127,717

         Pending   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

50605

  

Europe

NP

  

06-Nov-2008

61/193,220

   16-May-2011   

05-Nov-2009

09824498.1

         Pending   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

51983

  

Hong Kong

NP

         05-Nov-2009          Pending   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50606

  

Canada

NP

  

06-Nov-2008

61/193,220

   13-Apr-2011   

05-Nov-2009

2,740,726

         Pending   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

 

49

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


50608

  

Australia

NP

  

06-Nov-2008

61/193,220

   15-Apr-2011   

05-Nov-2009

2009312355

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50609

  

New Zealand

NP

  

06-Nov-2008

61/193,220

   19-Apr-2011   

05-Nov-2009

592357

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

50611

  

Japan

NP

  

06-Nov-2008

61/193,220

   06-May-2011    05-Nov-2009          Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50612

  

Republic of Korea

NP

  

06-Nov-2008

61/193,220

   02-Jun-2011   

05-Nov-2009

2011-7012700

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50613

  

Mexico

NP

  

06-Nov-2008

61/193,220

   04-May-2011   

05-Nov-2009

MX/a/2011/004773

         Pending    HALPERIN Gideon; KOVALEVSKI-ISHAI Eti; YACOV Niva; BREITBART Eyal; MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

 

50

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


50614

  

Russian Federation

NP

  

06-Nov-2008

61/193,220

   06-Jun-2011   

05-Nov-2009

2011122729

         Pending   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

50615

  

China

NP

  

06-Nov-2008

61/193,220

   30-Jun-2011   

05-Nov-2009

200980153378.2

         Pending   

HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;

YACOV Niva; BREITBART Eyal;

MENDEL Itzhak; ZINIUK Zeev; FEIGE Erez

 

ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC PROMOTER

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]          [***]          [***]    [***]
POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

02/23346

   PCT   

19-Oct-2001

60/330,118

     

01-May-2002

IL02/00339

  

Publ. Date: 24-Apr-2003

Publ. #: WO03/033514

      Expired    HARATS Dror; GREENBERGER Shoshana

27526

  

USA

NP

  

19-Oct-2001

60/330,118

   12-Apr-2004   

01-May-2002

10/490,746

  

08-Sep-2009

7,585,666

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

 

51

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


44506

  

USA

DIV

  

19-Oct-2001

60/330,118

   08-Aug-2008   

01-May-2002

12/222,439

  

02-Aug-2011

7,989,427

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

51506

  

USA

DIV

  

19-Oct-2001

60/330,118

   20-Jun-2011   

01-May-2002

13/163,767

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27527

  

Europe

NP

  

19-Oct-2001

60/330,118

   21-Apr-2004   

01-May-2002

02801473.6

  

22-Sep-2010

1436313

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

29028

  

Hong Kong

NP

  

19-Oct-2001

60/330,118

   06-Jan-2005   

01-May-2002

05100081.5

  

01-Apr-2011

HK1067641

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

49785

  

Europe

DIV

  

19-Oct-2001

60/330,118

   17-Sep-2010   

01-May-2002

EP10177257.2

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

47553

  

Europe

DIV

  

19-Oct-2001

60/330,118

   18-Nov-2009   

01-May-2002

09176343.3

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

49931

  

Hong Kong

DIV

  

19-Oct-2001

60/330,118

   10-Dec-2010   

01-May-2002

10111522.2

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

51004

  

Hong Kong

DIV

  

19-Oct-2001

60/330,118

   27-Apr-2011   

01-May-2002

11104228.3

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27528

  

Japan

NP

  

19-Oct-2001

60/330,118

   16-Apr-2004   

01-May-2002

2003-536253

  

22-Aug-2008

4,173,446

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27529

  

Republic of Korea

NP

  

19-Oct-2001

60/330,118

   17-Apr-2004   

01-May-2002

2004-7005720

  

24-Oct-2008

866117

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

 

52

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


27530

  

India

NP

  

19-Oct-2001

60/330,118

   19-Apr-2004   

01-May-2002

801/CHENP/2004

  

26-Dec-2008

226357

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27531

  

China

NP

  

19-Oct-2001

60/330,118

   09-Jun-2004   

01-May-2002

02824547.4

  

01-Jul-2009

ZL02824547.4

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

46077

  

China

DIV

  

19-Oct-2001

60/330,118

   27-Apr-2009   

01-May-2002

200910137707.6

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27532

  

Singapore

NP

  

19-Oct-2001

60/330,118

   16-Apr-2004   

01-May-2002

200402237-2

  

31-May-2006

103725

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27533

  

Canada

NP

  

19-Oct-2001

60/330,118

   16-Apr-2004   

01-May-2002

2,463,816

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27534

  

Mexico

NP

  

19-Oct-2001

60/330,118

   19-Apr-2004   

01-May-2002

PA/a/2004/003514

  

12-Nov-2010

280956

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

[***]

   [***]    [***]                [***]    [***]

27535

  

Australia

NP

  

19-Oct-2001

60/330,118

   20-Apr-2004   

01-May-2002

2002307793

  

17-May-2007

2002307793

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

27536

  

New Zealand

NP

  

19-Oct-2001

60/330,118

   16-Apr-2004   

01-May-2002

532348

  

12-Oct-2006

532348

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

 

53

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


27537

  

South Africa

NP

  

19-Oct-2001

60/330,118

   08-Apr-2004   

01-May-2002

2004/2756

  

31-May-2006

2004/02756

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal

 

USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN CARDIOVASCULAR, CANCER AND WOUND HEALING

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]          [***]          [***]    [***]

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

01/22752

   PCT   

17-Nov-2000

60/248,582

     

15-Nov-2001

IL01/01059

  

Publ. Date: 23-May-2002

Publ. #: WO02/40629

      Expired    HARATS Dror

26025

  

Europe

NP

  

17-Nov-2000

60/248,582

   15-May-2003   

15-Nov-2001

01996590.4

  

20-Jan-2010

1443970

      Granted    HARATS Dror; BLOOM Nira

29027

  

Hong Kong

NP

  

17-Nov-2000

60/248,582

   12-Jan-2005   

15-Nov-2001

05100240.3

  

20-Aug-2010

HK1068057

      Granted    HARATS Dror; BLOOM Nira

47088

  

Europe

DIV

  

17-Nov-2000

60/248,582

   04-Nov-2009   

15-Nov-2001

09174998.6

         Pending    HARATS Dror; BLOOM Nira

49806

  

Europe

DIV

  

17-Nov-2000

60/248,582

   01-Oct-2010   

15-Nov-2001

EP10185193.9

         Pending    HARATS Dror; BLOOM Nira

 

54

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


49498

  

Hong Kong

DIV

  

17-Nov-2000

60/248,582

   13-Oct-2010   

15-Nov-2001

10109698.4

         Pending    HARATS Dror; BLOOM Nira

52630

  

Hong Kong

DIV

  

17-Nov-2000

60/248,582

   2-Dec-2011   

15-Nov-2001

11113094.5

      3182.034HK21    Pending    HARATS Dror; BLOOM Nira

26026

  

Israel

NP

  

17-Nov-2000

60/248,582

   15-May-2003   

15-Nov-2001

155940

  

30-Mar-2009

155940

      Granted    HARATS Dror; BLOOM Nira

26027

  

India

NP

  

17-Nov-2000

60/248,582

   14-May-2003   

15-Nov-2001

743/CHENP/2003

  

20-Nov-2007

211599

      Granted    HARATS Dror; BLOOM Nira

26028

  

USA

NP

  

17-Nov-2000

60/248,582

   16-May-2003   

15-Nov-2001

10/416,917

         Abandoned    HARATS Dror

26029

  

Canada

NP

  

17-Nov-2000

60/248,582

   15-May-2003   

15-Nov-2001

2,429,342

         Pending    HARATS Dror; BLOOM Nira

26030

  

Australia

NP

  

17-Nov-2000

60/248,582

   15-May-2003   

15-Nov-2001

2002224002

  

26-Jul-2007

2002224002

      Abandoned    HARATS Dror

28653

  

Australia

DIV

  

17-Nov-2000

60/248,582

   01-Dec-2004   

15-Nov-2001

2003222427

  

09-Sep-2010

2003222427

      Granted    HARATS Dror; BREITBART Eyal; BLOOM Nira

49098

  

Australia

DIV

  

15-Nov-2001

2002224002

   25-Jun-2010   

15-Nov-2001

2010202660

  

1-Dec 2011

2010202660

      Granted    HARATS Dror; BREITBART Eyal; BLOOM Nira

26031

  

Japan

NP

  

17-Nov-2000

60/248,582

   16-May-2003   

15-Nov-2001

2002-543626

  

16-Jan-2009

4,243,653

      Granted    HARATS Dror; BLOOM Nira

 

55

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


26032

  

China

NP

  

17-Nov-2000

60/248,582

   16-Jul-2003   

15-Nov-2001

01822075.4

  

04-Feb-2009

ZL0182275.4

      Granted    HARATS Dror; BLOOM Nira

26033

  

Republic of Korea

NP

  

17-Nov-2000

60/248,582

   17-May-2003   

15-Nov-2001

2003-7006728

  

14-Nov-2008

869814

      Granted    HARATS Dror

44105

  

Republic of Korea

DIV

  

17-Nov-2000

60/248,582

   28-Jul-2008   

15-Nov-2001

2008-7018598

  

10-Sep-2009

917854

      Granted    HARATS Dror; BLOOM Nira

26034

  

Mexico

NP

  

17-Nov-2000

60/248,582

   16-May-2003   

15-Nov-2001

PA/a/2003/004325

  

15-Aug-2008

259670

      Granted    HARATS Dror

 

COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

28918

  

USA

CIP

  

04-Oct-1998

126447

     

17-Nov-2004

10/989,724

         Abandoned    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva
COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

30236

   PCT   

17-Nov-2004

10/989,724

     

25-Sep-2005

IL2005/001022

  

Publ. Date: 26-May-2006

Publ. #: |WO2006/054281

      Expired    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

39233

  

Europe

NP

  

17-Nov-2004

10/989,724

   13-Jun-2007   

25-Sep-2005

05788473.6

         Abandoned    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

 

56

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


42004

  

Hong Kong

NP

  

17-Nov-2004

10/989,724

     

12-Sep-2007

07109873.6

         Abandoned    HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

 

PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

28376

  

USA

CIP

  

17-Nov-2000

60/248,582

     

14-Nov-2004

10/988,487

  

6-Dec 2011

8,071,740

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

50225

  

USA

DIV

  

17-Nov-2000

60/248,582

   01-Feb-2011   

14-Nov-2004

13/018,447

  

26-June 2012

8,206,743

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

50927

  

USA

DIV

  

17-Nov-2000

60/248,582

   02-May-2011   

14-Nov-2004

13/098,512

         Aban    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47407

  

USA

DIV

  

17-Nov-2000

60/248,582

   13-Nov-2009   

14-Nov-2004

12/591,252

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

60001

  

USA

Con

  

17-Nov-2000

60/248,582

   13-July 2012   

14-Nov-2004

13/549,355

      3182.0370004    Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

 

57

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


30269

   PCT   

14-Nov-2004

10/988,487

     

14-Nov-2005

IL2005/001195

  

Publ. Date: 18-May-2006

Publ. #: WO2006/051545

      Expired    HARATS Dror; GREENBERGER Shoshana

[***]

   [***]    [***]    [***]    [***]          [***]    [***]

47087

  

Europe

DIV

  

14-Nov-2004

10/988,487

   28-Aug-2009   

14-Nov-2005

09168899.4

  

2 Nov 2011

2174668

      Grnated    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

49224

  

Hong Kong

DIV

      12-Oct-2010   

14-Nov-2005

10109638.7

  

15 June 2012

HK1143078

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

49804

  

Europe

DIV

  

14-Nov-2004

10/988,487

   01-Oct-2010   

14-Nov-2005

EP10185195.4

  

26 Sep 2012

2301586

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

49805

  

Europe

DIV

  

14-Nov-2004

10/988,487

   30-Sep-2010   

14-Nov-2005

EP10184033.8

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

39318

  

Australia

NP

  

14-Nov-2004

10/988,487

   08-Jun-2007   

14-Nov-2005

2005303385

         Allowed    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

 

58

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


51825

  

Australia

DIV

  

14-Nov-2004

10/988,487

      14-Nov-2005   

28 June 2012

2011205076

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

53691

  

Australia

DIV

  

14-Nov-2004

10/988,487

   15 June 2012   

14-Nov-2005

2012203578

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

39323

  

New Zealand

NP

  

14-Nov-2004

10/988,487

   05-Jun-2007   

14-Nov-2005

555612

  

08-Apr-2010

555612

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

47297

  

New Zealand

DIV

  

14-Nov-2004

10/988,487

   09-Oct-2009   

14-Nov-2005

580289

  

05-Apr-2011

580289

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

39324

  

South Africa

NP

  

14-Nov-2004

10/988,487

   05-Jun-2007   

14-Nov-2005

2007/04687

  

31-Dec-2008

2007/04687

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat

[***]

  

[***]

  

[***]

  

[***]

  

[***]

        

[***]

  

[***]

50629

  

Singapore

DIV

  

14-Nov-2004

10/988,487

   11-Apr-2011   

14-Nov-2005

201102612-7

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat

39315

  

Israel

NP

  

14-Nov-2004

10/988,487

   14-May-2007   

14-Nov-2005

183187

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

 

59

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


50104

  

Israel

DIV

  

14-Nov-2004

10/988,487

   31-Oct-2010   

14-Nov-2005

209034

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat

[***]

  

[***]

  

[***]

  

[***]

  

[***]

        

[***]

  

[***]

39317

  

Canada

NP

  

14-Nov-2004

10/988,487

   17-May-2007   

14-Nov-2005

2,587,469

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

39319

  

Japan

NP

  

14-Nov-2004

10/988,487

   14-May-2007   

14-Nov-2005

2007-540833

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

52137

  

Japan

Div

  

14-Nov-2004

10/988,487

   Sep 2011   

14-Nov-2005

2011-191492

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

39320

  

China

NP

  

14-Nov-2004

10/988,487

   13-Aug-2007   

14-Nov-2005

200580046412.8

         Aban    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

39321

  

Republic of Korea

NP

  

14-Nov-2004

10/988,487

   14-Jun-2007   

14-Nov-2005

2007-7013464

         Pending    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat; PELED Michael

 

60

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


39322

  

Mexico

NP

  

14-Nov-2004

10/988,487

   11-May-2007   

14-Nov-2005

MX/a/2007/005783

  

8 May 2012

299008

      Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat

52598

  

Mexico

Div

  

14-Nov-2004

10/988,487

      14-Nov-2005   

4 Sep 2012

303042

   3182.037MX11    Granted    HARATS Dror; GREENBERGER Shoshana; BREITBART Eyal; BANGIO Livnat

[***]

   [***]    [***]    [***]    [***]       [***]    [***]    [***]

 

Method for treating vascular inflammation and psoriasis

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

   [***]    [***]       [***]       [***]    [***]    [***]

 

61

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Treatment Of Inflammation

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]    [***]       [***]       [***]    [***]    [***]

53305

   PCT   

12 Dec 2011

61/569,545 and

12 Dec 2011

61/569,481

     

11 Dec 2012

PCT/US2012/068995

      3182.014PC01    Pending   

MENDEL, Itzhak;

FEIGE, Erez;

YACOV, Niva;

PROPHETE-MEIRAN, Oshrat; BREITBART, Eyal;

SALEM, Yaniv

 

62

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Treatment Methods Using Adenovirus

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

[***]

   [***]    [***]       [***]       [***]    [***]    [***]

 

TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS

Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

N/A

   USA CIP   

03-Mar-1994

08/254,015

     

28-Feb-1995

08395742

  

05-May-1998

5747340

   Originally assinged to Syntex USA. Licensed to VBL    Granted   

HARATS Dror;

KURIHARA Hiroki;

NANETTE BELLONI Paula; SIGAL Charles Elliott

 

METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS

 

63

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


Our Ref

  

Country

  

Earliest Priority

  

Entry Date

  

Filing Date

Application No.

  

Issue Date

Patent No.

  

SKGF Ref

  

Status

  

Inventor

N/A

   PCT   

08-Dec-2009

61/283,696

     

07-Dec-2010

US2010/059204

  

Publ. Date: 16-Jun-2011

Publ. #: WO/2011/071859

   As of June 2012, the applicant is also VBL    Pending   

KOLESNICK, Richard, N.

STANCEVIC, Branka;

SADELAIN, Michel;

FUKS, Zvi;

VARDA-BLOOM, Nira;

HARATS, Dror;

Trademark: VBL therapeutics & logo   

Our Ref

Client Ref

  

Country

  

Class

  

Earliest

Priority

  

Filing Date

Application No.

  

Registration Date

Registration No.

  

SKGF Ref

  

Status

    

47638

   Europe    5, 42 & 44      

03-Dec-2009

008730541

  

02-Jun-2010

008730541

      Registered   
Trademark: VASCULAR BIOGENICS   

Our Ref

Client Ref

  

Country

  

Class

  

Earliest Priority

  

Filing Date

Application No.

  

Registration Date

Registration No.

  

SKGF Ref

  

Status

    

42092

   Israel    42      

23-Aug-2007

203346

  

06-May-2009

203346

      Registered   

43074

  

USA

(Paris)

   42   

23-Aug-2007

203346

  

14-Feb-2008

77/397,305

  

22-Jun-2010

3,805,239

      Registered   

 

64

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


43075

  

Europe

(Paris)

   5, 42 & 44   

23-Aug-2007

203346

  

18-Feb-2008

006675599

  

20-Feb-2009

006675599

      Registered   
Trademark: VBL VASCULAR BIOGENICS LTD. & Device   

Our Ref

Client Ref

  

Country

  

Class

  

Earliest

Priority

  

Filing Date

Application No.

  

Registration Date

Registration No.

  

SKGF Ref

  

Status

    

42199

   Israel    42      

09-Sep-2007

203748

  

10-May-2009

203748

      Registered   

43602

  

USA

(Paris)

   42   

09-Sep-2007

203748

  

03-Mar-2008

77/411,204

  

22-Jun-2010

3,805,245

      Registered   

43603

  

Europe

(Paris)

   42   

09-Sep-2007

203748

  

04-Mar-2008

006721823

  

04-Sep-2009

006721823

      Registered   
Trademark: VTS   

Our Ref

Client Ref

  

Country

  

Class

  

Earliest

Priority

  

Filing Date

Application No.

  

Registration Date

Registration No.

  

SKGF Ref

  

Status

    

42198

   Israel    5      

09-Sep-2007

203747

  

06-May-2009

203747

      Registered   

43600

  

USA

(Paris)

   5   

09-Sep-2007

203747

  

03-Mar-2008

77/411,151

  

20-Oct-2009

3,697,519

      Registered   

 

65

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


43601

  

Europe

(Paris)

   5   

09-Sep-2007

203747

  

04-Mar-2008

006721484

  

20-Feb-2009

006721484

      Registered   
Trademark: VASCULAR TARGETING SYSTEM VTS   

Our Ref

Client Ref

  

Country

  

Class

  

Earliest Priority

  

Filing Date

Application No.

  

Registration Date

Registration No.

  

SKGF Ref

  

Status

    

41864

   Israel    5      

23-Aug-2007

203345

  

08-Sep-2009

203345

      Registered   

43072

  

USA

(Paris)

   5   

23-Aug-2007

203345

  

14-Feb-2008

77/397,328

  

18-May-2010

3,789,108

      Registered   

43073

  

Europe

(Paris)

   5, 42 & 44   

23-Aug-2007

203345

  

18-Feb-2008

006675896

  

29-Jan-2009

006675896

      Registered   

 

66

 

Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [***].


 

Trademark: VBL

  

Our Ref

Client Ref

  

Country

  

Class

  

Earliest

Priority

  

Filing Date

Application No.